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Protecting public and animal health
 Irish Medicines Board
To protect and enhance  
public and animal health 
through the regulation 
of human and veterinary 
medicines and medical  
devices available in Ireland,  
or manufactured in Ireland  
for Irish or export markets.
Our mission
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2008 bore witness to some of the most challenging 
conditions to face Ireland in decades. I would like to 
commend the management and staff of the IMB for their 
commitment to the delivery of objectives for 2008 as 
they met these challenges in a more constrained fiscal 
environment. In fact, 2008 saw the Board and its staff 
provide very high levels of delivery in all areas of our 
operations. This report records the IMB’s favourable 
position as an independent, public health focused and 
authoritative body and illustrates the effectiveness of a 
high quality, service-based organisation.
The fundamental principle of the IMB’s existence, which 
underpins all of its work, is to protect and enhance public 
and animal health through the effective regulation of 
medicines, medical devices and healthcare products 
available on the Irish market. While high productivity 
levels across all operations were delivered in 2008, this 
was achieved without sacrifice to the primary foundation 
of the IMB’s remit. 
During 2008, the number of enforcement cases initiated 
by the IMB for breaches of medicinal product legislation 
more than doubled to 3,037 from that recorded in 2007, 
with online purchasing of medicines and counterfeit 
medicines contributing considerably to this figure. 
One highlight for the year was the IMB’s participation 
in Operation Pangea, the first International Internet 
Day of Action. Co-ordinated by the World Health 
Organisation (WHO), INTERPOL and the Permanent 
Forum on International Pharmaceutical Crime, the IMB 
in conjunction with eight other countries took part in 
targeting the illegal online sale of medicines, resulting in 
the decommissioning of an Irish website. 
Demands for service and information supply from the 
IMB has increased year-on-year from all stakeholders, 
spanning healthcare professionals, consumers, interested 
parties through to the industry itself. This is reflected in 
the IMB’s decision to launch a new website to enhance 
interaction with all stakeholders and to ensure the easy 
Chairman’s 
Statement
The number of enforcement cases initiated 
by the IMB for breaches of medicinal product 
legislation more than doubled to 3,037
Pat O’Mahony  
Chairman
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accessibility to a complex and comprehensive range of 
healthcare information. The website is a major single 
source of information in Ireland and provides information 
on all aspects of medicine and medical device provisions 
in Ireland including safety, legislation, licensing, product 
availability and regular news and safety updates for users. 
In 2008, we received 2,742 adverse reaction reports, a 
record number of suspected adverse reactions in relation 
to human medicines. The availability of a new online 
reporting system, which enhances the ease with which 
people can report suspected adverse reactions, has 
contributed to this increased number of reports.
The IMB continues to share information with its 
EU colleagues at the European Medicines Agency 
(EMEA), working closely together on new practices and 
participating in consultations on licensing procedures. 
This strong alliance has contributed partly to the Human 
Medicines Department processing 17,829 applications 
for new medicines or changes to existing medicines in 
2008. In the field of consumer protection, the sharing 
of information with various professionals, as well 
as State and scientific bodies, is crucial for effective 
judgements and strategies. We extend our gratitude to 
scientific bodies, professional groups and representative 
organisations, as well as the EU and international 
scientific and medical organisations and industry whose 
co-operation and assistance helps maintain the highest 
standards of medicinal products on the Irish market. 
We thank the Minister for Health and Children and the 
staff at her Department for their ongoing support in our 
day-to-day workings. In addition, we also appreciate the 
assistance of the Department for Agriculture, Fisheries  
and Food. The continued co-operation of the dedicated 
professionals in these departments has and will continue 
to contribute to the productive operation of the IMB. 
Throughout 2008, the Board and advisory committee 
members of the IMB continued to demonstrate their 
commitment and dedication to the organisation through 
their individual expert contributions to our collective 
thinking. I would also like to take this opportunity to thank 
the individuals who comprise the various committees as 
they provide the IMB with unique access to best available 
advice. These committees, combined with our staff, have 
a strong level of scientific and healthcare professionalism 
and work commitment. This ensures that the IMB remains 
a key national driving force in the overall protection of 
public and animal health.
Many of you will be aware that, towards the end of 2008, 
the Minister for Finance announced the amalgamation 
of the Board with the Food Safety Authority of Ireland 
(FSAI) and the Office of Tobacco Control (OTC). This offers 
a platform for further development for the Irish Medicines 
Board as it will create a single entity with very substantial 
scientific and management expertise, which will provide 
many opportunities in terms of shared learning and 
practical and scientific experience to benefit public health. 
We look forward to working with the Department of 
Health and Children and our colleagues from the FSAI and 
the OTC in advancing this initiative and maximising the 
available synergies to enhance consumer health. Support 
for this proposal by Board members and the management 
executive has been most encouraging. 
With economic forecasts predicting a turbulent time 
ahead in the short to medium term, the IMB remains 
consistent in delivering on best practice to protect human 
and animal health through cost effective, high-quality and 
efficient actions. 
 
 
Pat O’Mahony 
Chairman
We received 2,742 adverse reaction reports, 
a record number of suspected adverse reactions 
in relation to human medicines
The Human Medicines Department processed 
7,829 applications for new medicines or 
changes to existing medicines in 2008
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The Board members are:
1. Mr. Pat O’Mahony (Chairman)   
Business and Banking Consultant
2. Prof. Brendan Buckley    
Clinincal Professor of 
Pharmacology, University College 
Cork
3. Mr. Pat Brangan    
Senior Veterinary Inspector, 
Department of Agriculture, 
Fisheries and Food
4. Mr. Wilfred Higgins    
Principal Engineering Advisor, 
Health Service Executive 
5. Ms. Ingrid Hook    
Senior Lecturer, School of 
Pharmacy & Pharmaceutical 
Sciences, Trinity College
6. Mr. Brendan McLaughlin   
Farmer & Elected Board Director 
in the Management Committee 
of ICSA
7. Ms. Cicely Roche    
Lecturer PTTCD & Consultant 
Pharmacist
8. Ms. Maureen Windle   
Practitioner in Public Sector 
Healthcare Management
The Board of the IMB was appointed on 
31st December 2005 by the Minister for 
Health and Children, Ms. Mary Harney in 
accordance with the powers conferred on 
her by subsection 2 of section 7 of the Irish 
Medicines Board Act, 1995 for the period 
ending 31st December 2010.
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Organisational Chart
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Dr. Mike Morris
Medical Devices Director
Ms. Ann O’Connor
Director of Veterinary Medicines
Dr. J.G. Beechinor
Director of Compliance
Mr. John Lynch
Quality Manager
Dr. Caitríona Fisher
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OVERVIEW OF 2008
I am pleased to report that 2008 was another successful 
year for the Irish Medicines Board with sustained 
achievement in meeting the organisation’s mission to 
protect and enhance public and animal health through 
the regulation of medicines, medical devices and 
healthcare products. Any public health issues within 
our remit which emerged during the year were handled 
efficiently and successfully with the protection of public 
health at the core of all our activities. 
As we strove to continuously improve efficiencies and 
standards across the organisation whilst amalgamating 
new areas of responsibility, the implementation and 
management of change continued to be a key driver 
within the IMB. As a part of this ongoing organisational 
change process the Board approved the combining of 
all human medicines, medical devices and all regulated 
human products into a new revised departmental 
structure in which one department would focus on 
licensing and registration activities for all human 
products, while the second would focus on safety matters 
for all human products. We also significantly enhanced 
the application of our quality management system and 
successfully managed the affairs of the IMB in line with our 
statutory obligation that income at least meets costs.
Ireland is an important global location for the 
pharmaceutical/biopharmaceutical and medical devices 
industries and products manufactured in Ireland are 
exported worldwide. Ireland is now the largest exporter 
of pharmaceuticals in the world. The successful delivery 
of the IMB’s regulatory role in these sectors contributes 
greatly to this ongoing success and to ensuring that 
appropriate standards are maintained to the benefit of 
patients and consumers. 
Chief Executive’s 
Report
The implementation and management of 
change continued to be a key driver within  
the IMB
Pat O’Mahony  
Chief Executive
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HuMAn MEDICInES
Our focus on the safety, quality and efficacy of human 
medicines extends throughout the full lifecycle of all 
products: from the provision of scientific advice, approval 
of clinical trials, through to the assessment of applications 
for granting, variation and renewal of marketing 
authorisations. A key focus in this area is post-marketing 
surveillance, which encompasses pharmacovigilance, 
investigating reports of quality defects and a programme 
of product sampling and analysis. At all stages, patient 
safety remains at the forefront of the IMB’s focus. A wide 
range of safety actions were implemented during the year 
across a variety of medicines. A significant number of 
variations were initiated, assessed and issued during 2008 
following identification of specific safety issues detected 
through adverse reaction reports, review of cumulative 
safety data and the literature which were discussed and 
evaluated at either national or European level. 
Output of applications mirrored input. During the 
year, the IMB processed 15,688 variations to product 
authorisations, 1,268 new product applications and 873 
renewals to product authorisations. 
Total output for new applications
COMPLIAnCE
The IMB’s Compliance Department continued to carry 
out good manufacturing practice inspections on the very 
substantial number of manufacturing sites operating in 
Ireland. It also contributed significantly to inspections 
of foreign sites on our own behalf or on behalf of the 
European Union. Good distribution practice inspections 
were conducted on the supply chain whilst tissues and 
cells and blood establishment sites were also inspected. 
Licensing and export certification activities relating to Irish 
sites were carried out as were good clinical practice and 
pharmacovigilance inspections.
Number of Inspections Completed in 2008
During 2008, a total of 3,037 cases involving breaches of 
medicinal product legislation were initiated, representing 
a more than doubling of cases from 2007. The IMB seized 
a total of 393,067 units of capsules, tablets, liquids and 
creams containing a variety of active substances. Market 
surveillance programmes, encompassing investigation of 
quality defects and recalls, and sampling and analysis, were 
operated. These included 128 human medicines recalls 
and 13 veterinary medicines recalls from the market. 
Where appropriate, the implementation of follow-on 
corrective and preventative actions was overseen. A total 
During 2008, a total of 3,037 cases involving 
breaches of medicinal product legislation were 
initiated, representing a more than doubling of 
cases from 2007
The IMB seized a total of 393,067 units of 
capsules, tablets, liquids and creams containing 
a variety of active substances
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of 409 medicinal products were sampled for analytical 
testing and / or checks on labelling and packaging 
compliance.
Analysis of enforcement case activity
MEDICAL DEVICES
Activity in the medical devices area continues to be a 
signifi cant part of the work of the IMB. During 2008, a 
total of 240 medical devices were registered, including 
95 in-vitro diagnostic medical devices and 145 general 
medical devices. The number of medical device 
compliance cases dealt with during the year was double 
that handled in 2007.  The IMB is dependent on the 
availability of fi nancial resources from the Department 
of Health and Children to fund this area of activity and 
continues to advocate for additional resources. 
The creation of a new departmental structure combining 
all human products will substantially enhance our overall 
abilities from 2009 onward. It is noted that a total of four 
clinical investigation applications were received during 
the year and it is hoped that this number will increase 
substantially. The IMB has the structure and resources to 
deal with an increased number of these applications.
Any public health issues relating to medical devices arising 
during the year were handled eff ectively and effi  ciently. 
Number of Medical Device compliance cases opened
VETERInARy MEDICInES
Animal health and welfare is of critical importance to the 
Irish economy and its reputation in relation to producing 
quality produce. The food industry is a very important 
sector in the Irish economy with exports of €8.2 billion 
recorded in 2008. The regulation of veterinary medicines 
plays a signifi cant part in assisting the prevention and 
treatment of disease, in enhancing animal welfare and in 
ensuring the safety of foods of animal origin. 
A record number of applications for authorisation of 
veterinary medicinal products were approved by the 
IMB in 2008, and we played a leading role acting as 
reference member state/rapporteur in the centralised, 
mutual recognition and decentralised procedures, acting 
as reference member state for 21 outgoing applications 
for decentralised or mutual recognition procedures. A 
signifi cant development during the year was the release 
of automated e-mails on milestone achievements during 
the application evaluation process. This feature allows 
applicants to better track progress on their applications. 
Any pharmacovigilance and public health issues relating 
to veterinary medicines arising during the year were 
handled effi  ciently and eff ectively. 
Import 1,056
Advertising 73
Counterfeit 33
Others 58
Retail 51
Internet 10
Wholesale 5
Mail order 1,751
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FInAnCE AnD CORPORATE AFFAIRS 
In line with increased activity within the organisation in 
2008, the Finance and Corporate Affairs Department 
expanded its output across its various activities. A 
substantial number of Freedom of Information (FOI) 
requests were processed during the year. The Human 
Resources function had a busy year with an increase 
in recruitment and training provision and the Board 
approved the establishment of a dedicated Human 
Resource function at executive level. The internal 
financial audit function conducted reviews of systems 
and reported directly to the audit subcommittee of the 
Board, in compliance with good corporate governance 
requirements.
IT AnD CHAnGE MAnAGEMEnT
The IMB’s progressive programme of change, involving 
both the ongoing updating of our information technology 
and a programme of organisational change continued in 
2008 with the Board decision to develop a new role with 
a dedicated focus on safety-related issues. This initiative 
represented a significant programme of work for the 
organisation during 2008. The existing Medical Devices 
Department and Human Medicines Licensing Department 
merged into a revised model of human products licensing 
and registration and human products safety monitoring. 
This revised structure will be implemented in 2009 and 
there is substantial interest from regulators in other 
countries in our approach. 
Development continued of our IT systems, and our online 
application and tracking system for the pharmaceutical 
industry continued to grow in popularity during 2008 
with many new companies signing up to use the system. 
The system has also attracted the interest of other 
regulatory bodies within the EU, and has been well 
received by the industry. 
The IMB website received a large number of visitors during 
2008 and approximately 10% of adverse reaction reports 
were received via the website during the year. 
The department also provided increased output during 
the year by way of staff training and IT support as required 
by the organisation. 
QuALITy MAnAGEMEnT AT THE IMB
During 2008, we made significant progress in the 
implementation of an IMB-wide quality system which 
brings major benefits to efficient workings of the 
organisation and we assisted in the establishment of a 
second cycle of a benchmarking of all European medicines 
agencies, which adds substantial value to the quality of 
decision-making on patient safety issues throughout the 
European network. The next planned assessment of the 
IMB under this process will take place in early 2009.
THE EuROPEAn REGuLATORy SySTEM AnD 
InTERnATIOnAL AFFAIRS
In 2008, the IMB continued to participate actively in 
the European Medicines Regulatory System through its 
involvement in EU committees and working parties. We 
continued to contribute at EMEA level and I continued in 
the role of chairman of the Management Board of EMEA. 
The IMB also continued to contribute very actively at 
the Heads of Medicines Agencies (HMA) level, providing 
part of the Permanent Secretariat to the HMA as well as 
co-chair and technical support to the process of quality 
improvement of the European network known as 
Benchmarking of European Medicines Agencies (BEMA). 
We were also engaged in the assessment of centralised 
applications for human and veterinary medicinal products 
as rapporteur and as reference member state in the mutual 
recognition and decentralised procedures and continued 
to meet all timelines in all these procedures in 2008. 
This was another active year in the European Medical 
Devices regulatory system with the IMB participating in 
a large number of meetings at EU level, including the 
Medical Devices Expert Group and the Classification and 
Borderline Working Group.
2008 was another active year in the European 
Medical Devices regulatory system with the IMB 
participating in a large number of meetings at 
Eu level
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The IMB also continued to represent Ireland at the 
European Pharmacopoeia, where Dr. Mike Morris, Senior 
Scientific Advisor, continued to contribute at the highest 
level. During 2008, Dr. Morris delivered on a range of 
significant technical projects for the IMB.
Information technology continues to be an important 
topic on the EU agenda as it works to facilitate better 
access of patients to information on medicines and swift, 
accurate and efficient sharing of relevant information 
between regulatory authorities throughout Europe. 
During 2008, the IMB’s Information Technology 
(IT) department was actively involved in EU IT 
implementation activities.
The IMB attended the third international summit of 
Heads of Medicines Agencies which followed on from 
our successful hosting of this summit in 2007. We will 
participate in the organising committee for the 2009 
meeting which will be hosted in Canada. 
COMMunICATIOnS
In 2008, the IMB continued to enhance its 
communication with various stakeholder groups with 
an interest in healthcare products. Information days for 
human medicines pharmacovigilance, traditional herbal 
medicines, veterinary medicines pharmacovigilance and 
the manufacturing industry stakeholders were held. These 
meetings attracted a large number of attendees and 
positive feedback was received.
A number of meetings with other organisations and 
individuals with particular interests in healthcare products 
were also hosted during the year. These included meetings 
with the Animal & Plant Health Association (APHA), the 
Association of Pharmaceutical Manufacturers of Ireland 
(APMI), the Irish Association of Health Stores (IAHS), the 
Irish Health Trade Association (IHTA), the Irish Medical 
Devices Association (IMDA), the National Standards 
Authority of Ireland (NSAI), the Irish Pharmaceutical 
Healthcare Association (IPHA), Pharmachemical 
Ireland, the Pharmaceutical Distributors Federation, 
Pharmaceutical Society of Ireland and the Pharmacy 
Union.
PuBLICATIOnS
During 2008 the IMB launched a number of valuable 
guidance documents as part of its communications 
efforts, all of which are available from our website (www.
imb.ie).
A number of editions of the IMB’s Medicinal Products 
Newsletter, Medical Devices Newsletter and Drug Safety 
Newsletter were published and are available on the 
website.
FREEDOM OF InFORMATIOn
Twenty-one requests were received under the Freedom of 
Information Act in 2008, compared with 19 in 2007.
THE FuTuRE 
The IMB faces new challenges and new opportunities 
for development in 2009 and beyond. The economic 
downturn is a challenge for all sectors and organisations. 
Strict controls on public sector recruitment will pose 
substantial challenges to ensuring we can deliver on 
our public health remit and services to industry. The 
Government’s announcement in the Autumn of 2008 
of the merger of the Irish Medicines Board with the Food 
Safety Authority of Ireland and the Office of Tobacco 
Control, to take effect from 1 January 2011, is of huge 
strategic significance. The Board and Executive look 
forward to making this merger process a success in every 
way and to assisting in creating a new product regulator 
which will deliver substantial public health benefit.
The overall workload for the organisation continues to 
increase and meeting this demand in the most efficient 
and effective way will require that we carefully scrutinise 
all aspects of our organisation to ensure we are working in 
the most optimal way. Implementing the revised human 
products structure will allow us to increase synergies as a 
Chief Executive’s Report  
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regulator of various sectors and technologies which are 
increasingly merging and combining to deliver new and 
innovative healthcare solutions for patients. 
Our objective will be to maintain the impetus for change 
across the organisation and continue to manage change 
to assist us in delivering ever higher standards of output 
to all stakeholders. In this regard, continuing to develop 
our performance management and quality management 
systems will be a priority. We look forward to being 
assessed by peers from within the European medicines 
regulatory network during 2009 and having our practices 
benchmarked against the best the system has to offer. 
Our staff’s expertise and experience are key assets to 
our organisation. We will continue to offer training and 
development opportunities so that we can continue to 
maintain and enhance the skills set required for the ever 
changing and increasingly complex areas under our remit. 
We will continue the roll-out of our ongoing innovation 
in IT development and linked organisational change 
during 2009. These will further develop our information 
technology systems and assessment activity with 
consequential major benefits to the IMB and its 
stakeholders. 
We will continue to review our funding provision and to 
look critically at our own cost base to ensure maximum 
use of resources. 
BOARD AnD STAFF MATTERS
In total, over 100 people contribute voluntarily to the 
work of the IMB through participation on the Board and 
various Committees. The Board and Committees had a 
very successful year in office and the access we have to 
this range of independent expertise and acumen is of 
immense value to the workings of our organisations. I 
thank each member for their individual contribution and 
commitment during 2008. 
I acknowledge the support of the Ministers and staff of 
the Departments of Health and Children, and Agriculture, 
Fisheries and Food for the work of the IMB. 
I welcome all new staff members who joined during 2008 
and express my personal appreciation to all the staff of the 
IMB for their continued generous support in achieving the 
Board’s objectives during the year. I look forward to the 
support of all staff in dealing effectively with the various 
challenges ahead, as we continue to strive for excellence 
in all aspects of our daily activities.
 
Pat O’Mahony 
Chief Executive
Continuing to develop our performance 
management and quality management systems 
will be a priority
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The IMB received a total of 2,742 suspected 
adverse reaction reports occurring in IrelandHuman Medicines
The Human Medicines Department had a very successful 
year in 2008. Safety monitoring of medicines on the Irish 
market continued to be a core priority and the key focus 
of all staff  of the department. The department witnessed 
a substantial increase in outputs related to licensing 
activities which was eff ectively managed by the staff . 
PHARMACOVIGILAnCE 
During 2008 the IMB received a total of 2,742 suspected 
adverse reaction reports occurring in Ireland, from 
healthcare professionals and pharmaceutical companies. 
The IMB greatly appreciates the contribution of busy 
healthcare professionals in reporting suspected adverse 
reactions, facilitating the continued surveillance of the 
safety of medicines. While the time-consuming nature of 
form-fi lling and the provision of follow-up information 
to the IMB is recognised, the collection and evaluation 
of comprehensive reports are essential to ensure that 
appropriately detailed case information is available for 
the continuous surveillance of the safety of medicines 
on the Irish market. Such reports are vital for the IMB to 
ensure that regulatory action or proposals take account 
of all available data, including information obtained from 
spontaneous reporting. 
The online reporting system available to healthcare 
professionals and patients/consumers was increasingly 
used during 2008, with 264 reports submitted by year-
end via this method. Access to the online reporting system 
is available through the IMB website at www.imb.ie. 
A primary objective of the IMB pharmacovigilance system 
is to provide information on new and emerging safety 
issues related to medicines in a timely fashion, aided 
by the website, which includes e-mail alerting facilities. 
Users of the IMB website have the option of registering 
their contact information with the IMB to enable them 
to receive direct and immediate notifi cation of safety and 
regulatory alerts and updates by e-mail or text message. 
To facilitate prompt access to these updates, users are 
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The online reporting system was increasingly 
used during 2008, with 264 reports 
submitted by year-end via this method
encouraged to avail of this option by registering at www.
imb.ie.
The IMB continued to encourage adverse reaction 
reporting and provided regular reminders about 
reporting in the Drug Safety Newsletter and in its regular 
publications in MIMS (Ireland) and the Irish Medicines 
Formulary (IMF). A number of presentations on 
pharmacovigilance and adverse reaction reporting were 
made to healthcare professionals as part of undergraduate 
and postgraduate training, as well as continuing education 
programmes. While pharmacovigilance uses many 
sources of data, the need for detailed and comprehensive 
spontaneous reports remains pivotal for signal detection. 
The IMB is committed to using these data to promote 
the safe use of medicines, manage risk judiciously and to 
communicate safety information in a timely manner. 
Breakdown of Reports by Source
Marketing Authorisation Holders  1,867*
General Practitioners 253
Hospital Doctors  152
Hospital Pharmacists 132
Hospital nurses 48
Community Care Doctors  82
Community Pharmacists 71
Community nurses 32
Patient/Consumers 48
Clinical Trials 44 
Dentists 1
Haemovigilance officers  5
Healthcare Professionals (other)  7
Total 2,742
* This increased figure includes more than 700 case reports received 
following company review of cumulative data from the National 
Poisons Information Centre.
 Individual case reports were followed up by the IMB, 
with feedback information provided to reporters, as 
appropriate. Relevant reports (i.e. serious, suspected cases) 
notified directly to the IMB by healthcare professionals 
were forwarded to the appropriate marketing 
authorisation holders and the European Medicines Agency 
(EMEA) within the agreed timeframes and formats. The 
IMB also continued to provide details of reports received 
to the WHO for inclusion on their international database.
DRuGS WITHDRAWn/SuSPEnDED FOR SAFETy 
REASOnS
Acomplia (rimonabant)
The IMB suspended the marketing and use of Acomplia in 
Ireland on 23 October 2008 following a recommendation 
issued by the European Medicines Agency (EMEA) on 
the same date. This national action was taken following 
review of the product by the EMEA’s Committee for 
Human Medicinal Products (CHMP) which concluded 
that the benefits of Acomplia no longer outweighed its 
risks and that the marketing authorisation should be 
suspended across the EU. 
Following assessment of the available information on the 
benefits and risks of Acomplia, including data from studies 
completed since it was granted a marketing authorisation, 
the CHMP confirmed an approximate doubling of the risk 
of psychiatric disorders in obese or overweight patients 
taking Acomplia compared to those taking placebo.
The CHMP considered that the new data from post-
marketing experience and ongoing clinical trials indicated 
that serious psychiatric disorders may occur more 
commonly than suggested by the initial assessment of 
Acomplia. The CHMP was also of the opinion that these 
adverse reactions could not be adequately addressed by 
further risk minimisation measures.
Information regarding the suspension and use of 
Acomplia in Ireland was distributed by letter, fax, 
and e-mail networks to healthcare professionals, 
Dr. Joan Gilvarry  
Director of Human Medicines
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with information also highlighted on the IMB’s and 
professional bodies’ websites, advising of the action taken 
and requesting that no further prescriptions for Acomplia 
should be written or dispensed. In addition, a recall of 
the product was undertaken to patient level and patients 
were advised via media statements that they should 
discontinue treatment with Acomplia and should consult 
their doctor or pharmacist to discuss treatment options.
SAFETy VARIATIOnS 
A significant number of variations were initiated, assessed 
and issued by the Pharmacovigilance Section during 
2008 following identification of specific safety issues 
detected through adverse reaction reports, review of 
cumulative safety data, the literature and other sources., 
which were discussed and evaluated at either national or 
European level. During 2008 these included variations 
related to the use of ACE inhibitors and angiotensin II 
receptor-antagonists during pregnancy and lactation; 
antidepressants and antiepileptic medicines and the 
risk of suicidal behaviour; carbamazepine and the risk of 
Stevens Johnson Syndrome; use of codeine-containing 
medicines during breastfeeding; domperidone and QTc 
prolongation; and the potential for interaction between 
aspirin and ibuprofen.
COMPAny LIAISOn
Advice on IMB pharmacovigilance reporting requirements 
was provided to marketing authorisation holders (MAHs) 
on request throughout the year. Anonymised cumulative 
adverse reaction data was provided to MAHs in respect 
of their products on request and, in the case of individual 
serious suspected adverse reactions associated with use of 
their products, on an expedited basis. 
Company/sponsor compliance with pharmacovigilance 
obligations was monitored on an ongoing basis through 
review and monitoring of the timeliness and quality of 
individual adverse reaction reports, evaluation of the 
follow-up information provided for individual reports, 
assessment of the quality and comprehensiveness of 
periodic safety update reports, annual safety reports 
and responses to IMB requests for pharmacovigilance 
data. The pharmacovigilance inspection programme 
continued in 2008, involving collaboration between IMB 
pharmacovigilance and Compliance colleagues.
The IMB held an Information Day dedicated to 
pharmacovigilance and safety related issues in November 
2008. The agenda covered a range of topical areas 
including risk management, periodic safety update 
reports, compliance-related matters and electronic 
adverse reaction reporting, with speakers from the 
UK, Netherlands and the EMEA, as well as the IMB. 
Approximately 150 participants, mainly from Irish and 
UK-based companies, attended on the day and feedback 
was very positive.
ELECTROnIC REPORTInG
The IMB continued to report all suspected serious 
adverse reactions occurring in Ireland electronically via 
EudraVigilance to the EMEA and to those companies with 
whom satisfactory testing has been completed. By the 
end of 2008, 120 companies were in production with 
electronic reporting to the IMB, with a further six in active 
testing.
Detailed information and guidance on electronic 
reporting is available from the IMB Guide to Electronic 
Submission of ICSRs and SUSARs Associated with Use 
of Human Medicines, which can be located under the 
heading ‘Publications’ on the website. Feedback was also 
provided to participating companies on an ongoing basis, 
and updates and items of current interest in relation to 
electronic reporting were included in the quarterly IMB 
newsletter for industry.
IMB staff participated at all EudraVigilance meetings and 
training courses organised by the EMEA throughout the 
year.
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A new adverse reactions database is currently being 
implemented to facilitate enhanced pharmacovigilance 
activities, with significant additional functionalities 
to support safety monitoring and data management 
activities.
InTERnATIOnAL COLLABORATIOn
CHMP Pharmacovigilance Working Party (PhVWP)
There was a total of 11 meetings of the CHMP’s PhVWP 
during 2008. During these meetings, the PhVWP 
evaluated potential signals and ongoing safety concerns, 
provided advice to CHMP and Member States on 
confirmation and quantification of risk and on regulatory 
options, as well as risk management and monitoring of 
the impact of regulatory action. The PhVWP also worked 
on setting standards for procedures and methodologies 
to promote good vigilance practice, communication and 
exchange of information and international cooperation. 
The PhVWP continued its regular interaction with the 
FDA through tele- and video-conferences held during its 
meetings. 
Information was provided by the IMB’s Pharmacovigilance 
Section in respect of all requests circulated via the Rapid 
Alert/Non-Urgent Information exchange system by other 
Member States. 
WHO
IMB staff participated at the annual meeting of national 
centres participating in the WHO international drug 
monitoring programme in October 2008. 
PuBLICATIOnS
As part of its commitment to ensuring access to 
information, the IMB also uses a number of publications 
to communicate important safety information to 
stakeholders in addition to its website sources. 
Three issues of the IMB’s Drug Safety Newsletter were 
circulated to doctors, dentists and pharmacists during 
2008. These included an update on the regulatory 
measures taken in relation to nimesulide, the outcome 
of safety reviews undertaken at EU level regarding 
antidepressants, erythropoietin-containing products and 
moxifloxacin, together with updates on bisphosphonates, 
heparin, HMG-CoA reductase inhibitors, methadone, 
rosiglitazone and varenicline. Ongoing experience with 
BCG vaccine was described, as well as a reminder of 
the recommendations for the isotretinoin pregnancy 
prevention programme, use of codeine during lactation, 
use of cough/cold medicines in children, and the potential 
for medication errors arising from confusion of the 
product names, Octaplas and Octaplex. The January 
2008 issue of the Drug Safety Newsletter also included a 
questionnaire for readers on their view of the document, 
frequency, content, layout etc. While a limited number of 
responses were provided, feedback was generally positive 
and will be considered in terms of the increased focus on 
education and information currently being developed 
in the context of implementation of restructuring of 
IMB activities. Copies of the Drug Safety Newsletter and 
updates on safety issues considered to be of public health 
interest published in the IMB’s regular articles in MIMS 
(Ireland) and the IMF during the year are available from 
the Publications section of the IMB’s website www.imb.ie
The IMB also communicates directly with stakeholders 
through the provision of information in response to 
requests, and continued to do so during 2008, as well 
as participating at various meetings aimed at facilitating 
continued co-operation and collaboration with healthcare 
professionals, the pharmaceutical industry and others.
HAEMOVIGILAnCE
The IMB continued its regular meetings with the 
National Haemovigilance Office (NHO) to review 
haemovigilance events reported, discuss issues of mutual 
concern, contribute to the development of guidance 
on haemovigilance reporting and to consider further 
By the end of 2008, 20 companies were in 
production with electronic reporting to the IMB, 
with a further six in active testing
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developments to facilitate monitoring and revised 
working practices necessary to meet the provisions of the 
EU and national legislation.
The EU Commission continued to progress harmonisation 
initiatives to develop a common approach to the provision 
of data by Member States through a Working Group on 
Haemovigilance. The IMB and NHO have participated at 
this group and it is expected that the guidance document 
will be finalised shortly. 
The IMB also attended the annual European 
Haemovigilance Network conference and the Serious 
Hazards of Transfusion symposium during 2008.
In line with the legislative requirement and following 
collaboration with the NHO, the IMB submitted an 
annual report on serious adverse reactions and events to 
the EU Commission during 2008. The report reflected 
information received from January to December 2007 and 
consisted of 107 serious adverse reactions, two of which 
were associated with more than one blood component 
and 32 serious adverse events. 
TISSuE AnD CELL VIGILAnCE
The IMB attended and participated at relevant vigilance 
and surveillance meetings during 2008 to facilitate 
monitoring and revised working practices necessary 
to meet the provisions of the legislation. This included 
continuing participation in the joint WHO/EU project 
for Standards and Training for the Inspection of Tissue 
Establishments and contribution to the Vigilance and 
Surveillance Medical Advisory Committee meetings. The 
latter group has proposed a system for the classification, 
reporting and management of adverse events and 
reactions in Europe and the IMB is currently participating 
in a pilot project with partner countries, utilising the 
system under consideration. 
During 2008, the IMB received 27 reports associated with 
use of tissues and cells, 25 of which met the reporting 
criteria, including five serious adverse reactions and 
20 serious adverse events. Each report was followed 
up individually, with feedback provided to reporters. 
Information on reporting requirements, including a Guide 
to Reporting Serious Adverse Reactions and Serious 
Adverse Events associated with Human Tissues and Cells 
and downloadable and on-line versions of the report 
forms, are available on the IMB’s website. 
In line with the legislative requirement, the IMB submitted 
an annual report on serious adverse reactions and events 
received to the EU Commission during 2008. 
LICEnSInG ACTIVITIES
New Products Authorised
During 2008 the IMB output for new product applications 
was 1,268. This comprised 206 new national and parallel 
import applications, 532 new mutual recognition (MR) 
and new decentralised (DCP) applications, 249 new 
centralised* and 281 transfer applications.
(*Total number of centralised applications complete in 2008, all of which 
may not be authorised by the European Commission at this point.)
The following table shows the distribution of these over 
the last number of years:
Total output for new applications
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Total output for renewal applications
The number of renewal applications received was 1,025.
CLInICAL TRIALS AuTHORISED
During 2008, 117 applications to conduct clinical trials 
were approved by the IMB. This represents a similar figure 
to that of 2006 and 2007 as depicted in the table below.
Total output for new clinical trials
This total output figure displays an increase primarily due 
to an increase in the number of applications submitted 
through the centralised and decentralised procedures.
VARIATIOnS AuTHORISED
During the year, there was an output of 15,688 variations 
to product authorisations for products authorised through 
the national or mutual-recognition procedures. This 
was an increase from 2007 due to a 12% increase in the 
number of variation applications received (16,225).
Total output for variation applications
REnEWALS AuTHORISED
During the year there was an output of 873 renewals to 
product authorisations for products authorised through 
the national or mutual-recognition systems.
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During the year, there was an output of 
5,688 variations to product authorisations 
for products authorised through the national or 
mutual-recognition procedures
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Four hundred and twenty-nine clinical trial amendment 
applications were approved, which represents a slight 
decrease from the 2007 figure of 485.
APPLICATIOn InPuT AnD OuTPuT REVIEW
While there was an increase in applications received 
during 2008, the total output also exceeded previous 
years as depicted below. 
Application input and output review
PERIODIC SAFETy uPDATE REPORTS
A total of 2,746 periodic safety update reports were 
submitted in 2008. This included reports on products 
authorised through the national, mutual-recognition, 
and centralised procedures and those submitted as part 
of EU work-sharing scheme. A total of 2,292 reports were 
processed during 2008. 
PAEDIATRIC APPLICATIOnS
In accordance with Article 45 of Regulation (EC) No 
1901/2006 (the ‘Paediatric Regulations’), marketing 
authorisation holders were required to submit line-listings 
of all paediatric studies for authorised products by 26 
January 2008. The IMB received line-listings for 5,792 
products and processed 5,606 during 2008. The EMEA is 
coordinating the assessment by delegated Member States 
of the studies detailed on the line-listings with a view 
to authorising paediatric indications. The IMB is actively 
participating in the process.
The Paediatric Regulations also require the submission of 
any new studies conducted in the paediatric population 
using authorised medicinal products (Article 46). The 
EMEA will also co-ordinate the assessment of these data.
The IMB participated in the Paediatric Committee 
established by the Regulations and acted as rapporteur for 
a number of paediatric investigation plans during the year. 
The IMB is currently in the process of collecting data 
on existing uses of medicinal products in the paediatric 
population for submission to the EMEA. These data will be 
reviewed by the Paediatric Committee and an inventory 
of therapeutic needs for the paediatric population 
developed. 
TRADITIOnAL HERBAL MEDICInES
The IMB established the Traditional Herbal Medicinal 
Products Registration Scheme on 31 August 2007. Under 
the simplified registrations scheme, applications may be 
made for a certificate of traditional use, for traditional 
herbal medicinal products which meet certain criteria 
regarding traditional use, safety and quality and are 
suitable for use without the intervention of a doctor. 
The national legislation states that no medicinal product 
may be placed on the market without a marketing 
authorisation or a certificate of traditional-use registration 
but it provides an exemption from this requirement 
until 30 April 2011 for traditional herbal medicinal 
products which are on the market in the State. Therefore, 
a transition period for the implementation of the 
registration scheme is currently in place. The IMB has only 
received a small number of applications to date.
The IMB held an information meeting with interested 
parties on the requirements of the registration scheme 
on 13 February 2008. The aim of the meeting was to 
offer regulatory advice to companies in order to facilitate 
15,000
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compliance with the requirement for registration within 
the defined timeline. Presentations were given by 
IMB staff from the Human Medicines and Compliance 
Departments and the IMB Classification Committee 
covering areas of relevance to traditional herbal 
medicines. Industry participants included members of the 
Irish Health Trade Association and the Irish Association 
of Health Stores. Feedback received was very positive. All 
presentations from the information meeting are available 
on the publications section of the IMB website.
EuROPEAn COMMITMEnTS
Our commitments to the European medicines regulatory 
system continued to be substantial during 2008. The 
department’s technical staff serviced committees and 
working parties at the EMEA, as shown in the table below.
Committee/ Working Party Delegate Duration/ Frequency
Committee for Human Medicinal Products  Dr David Lyons & Dr Patrick Salmon 4 days/ month
Committee for Orphan Medicinal Products Dr David Lyons & Dr Patrick Salmon 2 days/month
Co-ordination Group for Mutual-recognition  Dr Jayne Crowe  3 days/month 
and Decentralised Procedures (h) Mr Larry O’Dwyer 
Committee on Herbal Medicinal Products Dr Cora nestor & Dr Sinead Harrington 4 days/2 months
Paediatric Committee Dr Kevin Connolly  3 days/ month 
 Dr yvonne Looney
Gene Therapy Working Party  Dr Maura O’Donovan 6 days/year
Pharmacovigilance Working Party  Dr Eithne Rooney/Dr Almath Spooner 3 days/month
Safety Working Party  Dr Lorcan Allen 2 days/3 months
Quality Working Party  Ms Catherine Mc Hugh 3 days/2 months
Vaccine Working Party  Dr Tracy Keane 3 days/2 months
Scientific Advisory Groups  Dr Sheila Killalea 3 days/month
Efficacy Working Party  Dr Kevin Blake 2 days/3 months
Biological Working Party  Dr Vincent Irwin/Dr una Moore 3 days/month 
 /Ms Maeve Lally
Blood Products Working Party  Dr Tracy Keane 2 days/3 months
Clinical Trials Facilitation Group  Dr Peter Kiely 2 days/3 months
A total of 2,746 periodic safety update 
reports were submitted in 2008
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There were 04 reports of suspected adverse 
reactions associated with the use of veterinary 
medicinal products received by the IMB in 2008
Veterinary 
Medicine
The year under review can be characterised as one of 
performance, change and challenge. This was the fi rst full 
year of operation under the new management structure 
and work-ﬂ ow system. A report on pharmacovigilance 
monitoring is provided together with a detailed 
review of operational performance, customer service, 
organisational development and fi nancial outturn.
PHARMACOVIGILAnCE
There were 104 reports of suspected adverse reactions 
associated with the use of veterinary medicinal products 
received by the IMB in 2008. Eighty-seven of the reports 
originated from marketing authorisation holders, 
16 reports were received from veterinarians or other 
healthcare professionals and one report was submitted by 
an animal owner. In these reports, a total of 67 veterinary 
pharmaceutical products and 42 immunological products 
were identifi ed as possibly associated with adverse events. 
Suspected adverse events were reported in the following 
species: human (six reports), bovine (36), canine (35), 
equine (11), ovine (eight), feline (four), porcine (two) and 
rabbit (two).
Of the reports received, 71 related to suspected adverse 
reactions in the treated animals, 26 related to suspected 
lack of expected effi  cacy, one related to a withdrawal 
period and six reports involved suspected adverse 
reactions in individual users following exposure to a 
veterinary medicinal product. No regulatory action was 
taken in 2008 relating to issues of target animal or user 
safety as a result of spontaneous adverse reaction reports; 
however, on foot of pharmacovigilance information 
received during the year the withdrawal period of an 
authorised product was amended. 
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The Veterinary Department acted as Reference 
Member State for 2 outgoing applications for 
decentralised or mutual recognition procedures
Dr. J.G. eechinor  
Director of Veterinary Medicines
The IMB continues to strive to promote veterinary 
pharmacovigilance in Ireland; on 9 October 2008 a very 
successful veterinary pharmacovigilance information day 
for the veterinary pharmaceutical industry was held. 
OPERATIOnAL PERFORMAnCE
The department reached a record output of 1,371 units; 
this figure was comfortably ahead of the management 
target of 1,260 set in February 2008. The ‘Nimbus’ work-
flow system underpins the management of applications 
and also serves as a document management tool. 
As in previous years, the department focused on three 
main areas:
• Excellence in our work: 22 new or updated standard 
operating procedures were approved during the year; 
a new system for peer review of selected applications 
by the IMB’s Advisory Committee for Veterinary 
Medicines was rolled out; five audits of various 
procedures operated in the department were carried 
out under the IMB’s quality management system.
• Efficiency: The department processed all centralised, 
decentralised and mutual recognition applications in 
accordance with the agreed timetables. The number 
of applications held in the work-in-process queues 
declined from 762 units in December 2007 to 690 
units in December 2008. December saw the roll-out of 
automated metrics on certain key internal processes 
for the first time in the IMB. Although the system must 
be further refined and tested it is expected that it will 
be a major help in performance management in 2009.
• Added-value: This service to industry supports Irish 
and European jobs and places the IMB in second place 
in Europe for such work.
November 2008 saw the introduction of the new 
requirement for applicants to notify the IMB of the 
marketing status of their products in this country. 
CuSTOMER SERVICE
A significant development during the year was the release 
of automated e-mails on milestone achievements during 
the application evaluation process. This feature allows 
applicants to better track progress on their applications. 
During the year the IMB conducted two web-based public 
consultations with stakeholders: the first was one relating 
to the range of IMB services which customers would 
be willing to pay for; the second relating to the annual 
fee review. The department also conducted a survey of 
marketing authorisation holders to gauge their familiarity 
with the requirements for pharmacovigilance systems 
for recording and reporting suspected adverse reactions. 
In addition to conducting this survey, the department 
held a Pharmacovigilance Information Day meeting on 9 
October 2008.
The department contributed articles to the three IMB 
Newsletters during the year and published two articles 
on the regulation of veterinary medicines in the Irish 
Veterinary Journal.
As in previous years, staff from the department held a 
number of meetings with stakeholders, including the 
Department of Agriculture, Fisheries and Food (DAFF).
The Director of Veterinary Medicines was active in a 
European task-force on legislation and delivered a 
presentation to a special conference on the topic of future 
availability of veterinary medicines to an international 
audience in Paris on 30 September. 
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Concerning national issues on veterinary medicinal 
matters, department staff also provided input into 
regulatory seminars on veterinary medicines to the 
Royal College of Surgeons in April and to the DAFF in 
December. The IMB approved a number of minor-use 
products during the year including a vaccine for rabbit 
haemorrhagic disease, hyperimmune serum for foals and 
two lice treatments for salmon. As provided for in national 
legislation, in June 2008 the IMB accepted an ivermectin-
containing product intended for use in pet rabbits and 
ferrets, as not requiring a marketing authorisation. 
ORGAnISATIOnAL DEVELOPMEnT
The vision of the management team for the department 
at the time of its reorganisation in 2007 was to develop 
‘an inspired and fulfilled team delivering an innovative, 
informative and responsive regulatory system for 
veterinary medicines which enhances the lives of animals 
and safeguards the health of society.’ Throughout 2008 
the IMB underwrote the development of the department 
to realise this vision through its recruitment of staff 
and the provision of training. A senior staff member 
was accepted as an expert assessor to the European 
Directorate for the Quality of Medicines; this work 
involves the assessment of drug master files for EU-wide 
suitability and is undertaken in short blocks of time at 
intervals during the year. Two more of the current staff 
have embarked on Masters degrees while a change of 
representation for CVMP and CMDv meetings was agreed 
by year-end. 
22 new or updated standard operating 
procedures were approved during the year
Veterinary Medicines  
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As part of its organisational planning during 2008, the 
management of the department identified some changes 
to the business model to improve capacity to handle high-
value applications, to increase efficiency and to strengthen 
the pharmacovigilance unit to meet the requirements of 
the legislation for enhanced monitoring. Before year-
end Board approval for the changes was given and it is 
expected that the changes will be put into effect early in 
2009. 
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Ms. Ann O’Connor 
Medical Devices DirectorMedical Devices
The year 2008 was a busy and productive year for 
the Medical Devices Department with continued 
increases in activity levels. The department completed 
the implementation of its new structure, undertook 
signifi cant process re-engineering and put in place 
additional resources. The new structure has supported 
an increased focus on operational management and an 
integrated focus on market compliance activities.
Monitoring of safety issues on the Irish marketplace 
continued to be a key day-to-day activity. Signifi cant 
activity took place in the areas of vigilance, compliance 
and clinical investigations. 
The Advisory Committee for Medical Devices (ACMD) 
met three times during 2008. Topics under consideration 
included development of information on the use of 
medical devices in the community setting, point-of-care-
testing, review of the medical devices directives, vigilance 
issues and monitoring of the outcome of notifi ed body 
audits. The ACMD also assisted with the development of 
a series of brochures which are directed at the public to 
create awareness of medical devices. It is expected that 
these brochures will be published in the second quarter of 
2009.
The Medical Devices Department, in partnership with 
chemical pathologists, clinical biochemists and medical 
scientists produced Guidelines for Safe and Eff ective 
Management and Use of Point of Care Testing (POCT) 
within the hospital environment. This document was 
launched in April 2008 by the Minister for Health 
and Children, Mary Harney, TD. Following on from 
this, the IMB established a new working group to 
develop guidelines for point-of-care testing in primary, 
community and continuing care settings e.g., pharmacies. 
The guidelines are currently at an advanced stage and it is 
hoped that the fi nal guideline will be published in 2009.
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During 2008 assistance was provided to the Department 
of Health and Children on the transposition of Directive 
2007/47/EC into Irish law via S.I. No 109 of 2009 
European Communities (Active Implanatable Medical 
Devices) (Amendment) Regulations 2009 and S.I. No 
110 of 2009 European Communities (Medical Devices) 
(Amendment) Regulations 2009. 
In May 2008, the European Commission published a 
questionnaire for stakeholders with various proposals to 
‘recast’ the medical devices directive, Directive 93/42/EEC. 
The IMB submitted a comprehensive response to this 
questionnaire following consultation with various relevant 
national stakeholders and has remained involved in 
discussions at a European level with other Member States 
and the European Commission.
VIGILAnCE 
A total of 1,160 vigilance reports were received and 
assessed in 2008, which represented an increase of 38% 
on the number of reports received in 2007. This increase 
was due to multiple factors including the implementation 
of the MEDDEV 2.12-1 rev 5 Guideline on a Medical 
Devices Vigilance System which came into force on 1 
January 2008. This resulted in a significant increase in the 
number of national Competent Authority reports being 
circulated by Member States as a result of the improved 
clarity in the revised guidance on the medical device 
vigilance system. A total of 434 national Competent 
Authority reports were circulated by European Competent 
Authorities in 2008 with the IMB issuing 58, an increase 
of 49% from 2007. 
Of the vigilance reports received in 2008, 38% were 
from manufacturers or their legal representatives, 51% 
were from other regulatory agencies (including web 
postings) and 9% were received directly from medical 
device users. Class IIa and IIb general medical devices and 
general category in-vitro diagnostic (IVD) medical devices 
represented the largest number of reports received. 
In the Class I/IIa group there was an increased trend in 
reports relating to reusable instruments and hospital 
hardware. In the Class IIb/III group there was a higher than 
usual number of orthopaedic implant recalls. A number 
of reports were also received regarding implantable 
neurological devices.
Overall, in general medical devices, there has also been 
an increased trend in recalls relating to device packaging 
sterility, software issues particularly with diagnostic and 
treatment planning software, and an increased trend 
in reports relating to single-use devices. Single-use, 
diagnostic and therapeutic radiation, and electro-
mechanical medical devices represented the most 
common reports received per product family. Single-use 
devices include items such as infusion and transfusion 
sets. 
In the IVD area the largest number of reports related 
to clinical biochemistry and microbiology devices. An 
increased number of vigilance cases relating to pregnancy 
tests were received in 2008. Vigilance issues with blood 
glucose meters also accounted for a large number of IVD 
clinical biochemistry cases. Software upgrades for clinical 
chemistry analysers also had a high impact on the number 
of IVD clinical biochemistry vigilance cases.
During 2008, the IMB received 885 field safety corrective 
actions relating to medical devices that directly impacted 
the Irish market. These resulted in a combination of 382 
product removals, 249 field safety notices, 136 software 
upgrades, 117 field modifications and one case of user 
training. The implementation of corrective actions was 
closely monitored by the Medical Devices Department. 
,60 vigilance reports were received and 
assessed in 2008, an increase of 38% on the 
number of reports received in 2007
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Family Groups of Devices Implicated in Vigilance 
Reports in 2008 – In-vitro Diagnostic Medical 
Devices (completed)
Outcome of field safety corrective actions in 2008
Number of vigilance reports received
Family Groups of Devices Implicated in Vigilance 
Reports in 2008 – General Medical Devices and 
Active Implantable Medical Devices
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nOTIFIED BODIES 
The IMB conducted three surveillance audits of the 
National Standards Authority of Ireland (NSAI) during 
2008 to the Medical Device Directive, the Active 
Implantable Medical Device Directive and the In-vitro 
Diagnostic Medical Device Directive. Two surveillance 
audits were conducted at the NSAI offices in Dublin 
and one audit in NSAI’s offices in New Hampshire, USA. 
Issues were identified during the audits which are being 
addressed by the NSAI. The IMB will continue to closely 
monitor Irish notified bodies during 2009.
Two satisfactory observed audits were conducted on NSAI 
auditors during 2008, one on an Irish-based auditor and 
the other on a US-based auditor. 
The IMB has committed to continue its participation in, 
and assistance with, further development of the peer 
review scheme for Notified Body audits operated by the 
Notified Body Operations Group. 
CERTIFICATES OF FREE SALE 
In 2008, 434 certificates of free sale for medical devices 
were issued. The quality of the applications and related 
documentation for certificates of free sale received from 
medical device manufacturers were significantly improved 
in comparison to 2007. 
REGISTRATIOnS 
 There were 240 new notifications to the register for 
medical devices in 2008. A total of 95 in-vitro diagnostic 
medical devices and 145 general medical devices were 
registered. The number of new organisations registered 
was 17. The data collected on the registration database 
were uploaded on a monthly basis throughout 2008 to 
the European Commission’s EUDAMED database. 
CLInICAL InVESTIGATIOnS 
During 2008, four clinical investigation applications 
for general medical devices were received and two 
significant amendments to previously authorised clinical 
investigations. One of the clinical investigations submitted 
was subsequently withdrawn by the manufacturer. One 
application was approved to make a non-CE marked 
cardiology device available for use on compassionate 
grounds.
The IMB continues to promote communication with 
manufacturers and other investigation sponsors on 
clinical investigation issues. This approach, including 
pre-submission queries and meetings, helps to clarify 
expectations and data requirements and facilitates 
the review process. During 2008, the IMB, following 
consultation with research ethics committees, published 
a Guide for Ethics Committees relating to medical device 
clinical investigations. 
CLASSIFICATIOnS 
Seventy two classification queries were received in 2008: 
50% of the queries originated from other Competent 
Authorities and 23% from other external stakeholders. 
Of the 72 classifications, 23 related to drug-device 
combination or borderline products and were referred to 
the IMB’s Classification Committee. 
A number of these 72 queries require further discussion at 
the European Medical Devices Expert Group Classification/
Borderline Working Group. 
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Source of Classification Queries
POST-MARKET SuRVEILLAnCE ACTIVITIES 
Audit
A total of 54 medical device audits were completed in 
2008, comprising 16 proactive audits (largely Class I 
products), one reactive audit (Class IIb product), 32 audits 
of custom-made medical device manufacturers and five 
Notified Body audits. 
The majority of non-compliances raised during the 
proactive audits related to inadequate implementation 
of the new MEDDEV 2.12/5 Medical Devices Vigilance 
System and inadequate technical documentation.
As a result of the IMB’s focus on custom-made device 
manufacturers, all registered manufacturers of assistive 
products for persons with disability have now been 
audited by the IMB with all identified issues resolved to 
the benefit of users.
Compliance
During 2008, 380 compliance cases were opened, which 
represented an increase of 101% on the figure for 2007. 
Class IIa and IIb general medical devices represented 
the largest number of compliance cases with single-use 
medical device representing the most common type of 
case.
Of the compliance cases received, 87% were notified to 
the IMB by other Competent Authorities and related to 
notified body certificate withdrawals or issues that were 
of concern in another Member State. Problems identified 
and investigated as part of compliance cases in 2008 
included labelling, missing or incorrectly attached CE 
marking and classification issues. In 2008, there were also 
a small number of compliance cases relating to counterfeit 
medical devices. 
Number of compliance cases opened
The second phase of the proactive compliance activity on 
system and procedure packs focused on systems. Follow-
up corrective actions arising from a number of compliance 
audits conducted in 2007 were concluded in 2008. 
Contribution and support was also provided to the 
European working group that is planning co-ordinated 
market surveillance activity at EU level. 
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A total of 54 medical device audits were 
completed in 2008
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PuBLICATIOnS
In 2008, the following guidance documents were 
published or updated for stakeholders:
Guide for Class I Manufacturers on compliance with 
European Communities (Medical Devices) Regulations, 
1994
Guide for Custom-made Medical Device Manufacturers 
on Compliance with European Communities (Medical 
Devices) Regulations, 1994
Guide to Applications for Certificates of Free Sale for 
Medical Devices
Guide to Drug-Device Consultations
Guidelines for Safe and Effective Management and use 
of Point of Care Testing
Guide for Ethics Committees on Clinical Investigation of 
Medical Devices
The IMB Safety Notices which were circulated in 2008 
were:
IMB Safety notice Sn2008(01):  
Intra Stent
IMB Safety notice Sn2008(02):  
Fast Fluid Warmer
IMB Safety notice Sn2008(03):  
Baby Beets Fetal Doppler
IMB Safety notice Sn2008(04):  
Coopers Walking Frames
IMB Safety notice Sn2008(05):  
Clinitest Pregnancy Test Kits
IMB Safety notice Sn2008(06):  
Disposable Infusion Devices
IMB Safety notice Sn2008(07):  
Bench-top Steam Sterilisers
IMB Safety notice Sn2008(08):  
Blood Bags and Giving Sets
Three medical device newsletters were issued during 
2008 which continue to be well received by stakeholders. 
Many contributions were received towards newsletter 
articles from academia, the healthcare sector and industry, 
highlighting many different medical device issues. 
COMMunICATIOn 
During 2008, the IMB made presentations at many 
stakeholder conferences including the National Standards 
Authority of Ireland (NSAI) Information Day on revision of 
the medical devices directives. 
The IMB continued participation in Consultative Groups 
with the Faculty of Pathology, the Academy of Medical 
Laboratory Science and the Association of Clinical 
Biochemists in Ireland to develop guidance for the safe 
and effective management and use of point-of-care 
testing in the healthcare setting. Having published 
guidance for point-of-care testing use in the clinical 
setting during 2008, work commenced on developing 
a similar guidance for point-of-care testing use in the 
primary, community and continuing care setting.
The IMB continued participation in several stakeholder 
workgroup including the MERIT group on automated 
external defibrillators which published a guidance 
document during 2008 for relevant stakeholders on 
considerations when purchasing a defibrillator.
Throughout 2008, the IMB continued its regular meeting 
schedule to communicate on key medical device issues 
with stakeholders including the Department of Health 
and Children, the NSAI and the Irish Medical Device 
Association. 
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In 2008, a significant focus was placed on the 
surveillance and notified bodies at an Eu level to 
ensure consistency of performance
EuROPEAn ACTIVITy 
During 2008, the IMB continued to actively participate in 
European meetings of the Medical Devices Expert Group 
and the related working groups. Delegates from the IMB 
acted as the chair for the newly-created Compliance and 
Enforcement Working Group (COEN) and vice-chair of the 
Notified Body Operations Group (NBOG). A significant 
focus is being placed on the surveillance of notified bodies 
at an EU level to ensure consistency in performance.
The IMB continued its participation in the Clinical 
Evaluation Task Force which has completed its original 
terms of reference. The task force is to become a 
permanent working group during 2009 as the Clinical 
Investigation and Evaluation Working Group. The IMB 
participated actively in the subgroup to develop the clinical 
module of the Commission’s EUDAMED medical device 
database.
Ireland presented at and participated in two meetings of 
the Presidencies of the EU, namely Slovenia and France.
COSMETICS
In 2008, a report was prepared and submitted to 
the Department of Health and Children detailing the 
legislative obligation and responsibilities, and the 
functions that need to be undertaken by the IMB if it were 
to assume the role of Competent Authority for cosmetics 
in Ireland. This report also detailed the proposed 
structure, staff, cost, proposed funding mechanisms 
and requirements for the IMB in assuming this role. 
The compilation of the report involved close interaction 
with the current Competent Authority (Department of 
Health and Children) and other stakeholders, including 
the European Commission, National Consumer Agency, 
Health Service Executive and industry representative 
bodies. The activities of the European Council Working 
Group on Cosmetics were closely monitored, as a recast 
of the Cosmetics Directive is proposed for adoption which 
aims to strengthen the legislation in a number of key 
areas including definitions, good manufacturing practice 
and post-market surveillance. The IMB also attended as 
an observer at a number of European meetings relating to 
cosmetics including the Standing Committee on Cosmetic 
Products, the Working Group on Cosmetic Products, and 
the Platform of European Market Surveillance Authorities 
in Cosmetics. 
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Compliance
The year 2008 was another busy year across all the 
department’s activities. The key activities are outlined 
below. 
LICEnSInG
The total number of licences and authorisations in force at 
year-end is presented below by category.
Total Number of Licences 
/ Authorisations (Sites) 2006 2007 2008
Human  82 85 86
Veterinary  30 28 26
Investigational 
Medicinal Products  36 43 45
Wholesaler 148 127 214*
Blood Establishments 1 4 6
Tissue Establishments  0 0 6
Laboratory Certifi cates 8 12 11
* Includes wholesalers supplying general sale products only
The Licensing section continued to support the Inspection 
section with regard to the issuing of GMP certifi cates 
within 90 days following an inspection.
Controlled Drugs 
Licensing Activity   2006 2007 2008
Registration  26 19 23
Export & Import 944 964 1056
Annual – new 20 19 19
Annual - Renewal  152 171 243
Letter of no Objection 431 473 489
Pilgrims 12 14 14
Hemp 0 5 46
In 2008 there was an output of ,876 export 
certifi cates
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EXPORT CERTIFICATES 
There was an output of 1,876 export certificates as set out 
below.
Product Certification Activity  2006 2007 2008
Certification of Documents 389 316 266
Certificates of Free Sale 35 52 22
Certificate of Good Manufacturing  
Practice for Finished Product  
Manufacturers 224 200 212
Certificate of Good Manufacturing  
Practice for Active Substance  
Manufacturers 43 62 42
Certificate of a Pharmaceutical  
Product for Human use 1,193 941 1,236
Certificate of a Pharmaceutical  
Product for Veterinary use 97 105 37
Other 69 82 61
Total 2,050 ,758 1,876
Eu PROJECTS
The EMEA launched the EudraGMP database in April 
2007. It contains information on all manufacturing and 
importation authorisations issued by EEA competent 
authorities, as well as information on GMP certificates 
issued by Member States following each GMP inspection. 
During 2008, the Licensing section and the IT and Change 
Management department continued to participate in the 
EudraGMP EMEA project group. 
With around 15,000 importers and manufacturers in the 
EEA, up to 7,000 new GMP certificates will need to be 
entered into the database each year. GMP certificates are 
issued following satisfactory inspections in third countries 
and those relating to inspections of active substances, and 
certain excipients, will also be included. 
EEA competent authorities currently have full read/write 
access to the EudraGMP database. Access to the general 
public for manufacturing and importation authorisations 
and certain GMP certificates, with the exception of 
any information of a commercially and/or personally 
confidential nature, is planned for a future release. 
Discussions with MRA partners are ongoing with the aim 
of substituting the paper exchange of certificates.
InSPECTIOnS
Good Practice Inspection Activities
The IMB’s Compliance inspections function is structured 
within four operational groups:
• Good Manufacturing Practice (GMP)
• Controlled Drugs and Good Distribution Practice (CD / 
GDP)
• Good Clinical Practice and Pharmacovigilance (GCP/
PhV) 
• Blood and Tissues 
Good Manufacturing Practice (GMP)
One hundred and twenty one GMP inspections were 
performed. These included 23 inspections in non-EEA 
countries, nine of which were carried out at the request 
of the EMEA for centrally-authorised products, and two 
inspections at the request of the European Directorate 
for Quality of Medicines (EDQM) of an active substance 
manufacturing site named on a Certificate of Suitability 
to a monograph of the European Pharmacopoeia. 
The remaining foreign sites were included on Irish 
manufacturers’ authorisations as third country 
manufacturing sites or as manufacturers named in 
marketing authorisations for medicinal products.
Good Distribution Practice (GDP)
Sixty six GDP inspections were performed to ensure 
continued compliance with GDP requirements and to 
assess applications for new authorisation or variations to 
existing authorisations.
Mr. John Lynch  
Director of Compliance
2 Good Manufacturing Practice (GMP) 
inspections were performed. These included 
23 inspections in non-EEA countries
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The programme included a number of inspections of 
wholesalers involved in the distribution of parallel-
imported medicinal products to assess the compliance of 
products supplied to the market.
Controlled Drugs Inspections
Fifteen controlled drugs inspections were performed. 
The programme focussed on licensed distributors and 
manufacturers of controlled drugs.
Good Clinical Practice (GCP) 
The GCP inspection programme includes inspection 
of sponsor companies, investigators, contract research 
organisations and laboratories, and applies to clinical trials 
approved in Ireland and those performed in support of 
national / EU marketing authorisations. 
Sixteen GCP inspections were performed. Of these, 14 
were carried out at investigator sites in Ireland. In addition 
two inspections were conducted at the request of the 
EMEA at a sponsor site and a study site in a non-EEA 
country as part of the assessment of an application for an 
EU marketing authorisation. 
Pharmacovigilance Inspections
One pharmacovigilance inspection was performed at an 
Irish-based marketing authorisation holder’s facility.
Blood Establishment and Blood Bank Inspection 
Ten blood establishment inspections were performed.
Twenty two hospital blood banks, two facilities (where 
transfusion only occurs) and one storage facility were 
inspected. This programme of inspections was based on 
the IMB’s review of hospital blood bank annual reports 
for 2007. The focus of these inspections was to assess the 
progress of the hospital blood banks in attaining the ISO 
15189 accreditation standard as required by legislation.
At the request of the Maltese Medicines Authority, a 
member of the Blood and Tissues team participated in 
an inspection at the Maltese Blood Transfusion Service 
to assist that agency in the development of its national 
inspection programme. 
Tissue Establishment Inspections 
Fifteen tissue establishment inspections were performed. 
The main focus of the inspection programme was on 
applications for tissue establishment authorisations made 
by a number of assisted human reproductive clinics and 
hospitals.
Performance Targets
On the 31 March 2008 the inspection reporting procedure 
was improved by the introduction of a 15 day target for 
reporting deficiencies to the site which was inspected. 
Its purpose was to facilitate a faster response from the 
manufacturer to any deficiency in good practice identified 
during the course of an inspection. The target for issuance 
of the full inspection report remained at 28 days post- 
inspection. 
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MARKET COMPLIAnCE
Overview
The Market Compliance section runs a number of risk-
based, compliance–related programmes. These include:
• proactive market surveillance activities, such as the 
sampling and analysis programme
• reactive market surveillance activities, such as those of 
the quality defect and recall programme
• exempt medicinal products programme which is a 
notification system relating to the importation and 
supply of unauthorised medicinal products in Ireland
• regulatory compliance inspections at the premises 
of marketing authorisation holder companies. 
This programme is designed to assess the level 
of compliance against various items of national 
legislation pertaining to the marketing and advertising 
of medicinal products. 
In the following sections, a summary of the activities for 
2008 in each of the above areas is presented.
Sampling and Analysis Programme
The sampling and analysis programme is a risk-based 
programme and includes authorised medicinal products, 
products manufactured in Ireland for export only, active 
substances, enforcement-related samples and borderline 
products.
Products sampled are either subjected to analytical testing 
and/or packaging and labelling examination work. A total 
of 409 medicinal and other product types were tested or 
examined, comprising approximately 800 different tests. 
Two areas of particular focus were the quality of active 
substances imported into Ireland from non-EEA countries, 
and the compliance of medicinal product packaging and 
labelling with marketing authorisation requirements. 
Analytical Testing Activities
A significant portion (24%) of the programme was 
devoted to the analysis of active substances manufactured 
in non-EEA countries and used at Irish manufacturing 
sites. Approximately 40% of the analytical work 
was directed at authorised medicinal products, and 
approximately 36% related to enforcement and borderline 
product samples. 
The table below provides details of the product categories 
tested. 
Information on the product categories  Number of 
subject to Analytical Testing in 2008 samples 
Physico-chemical & Biological Analysis:
Active Substances 54
nationally authorised medicinal products 33
Parallel import licences 8
Products manufactured for export 1
Borderline products 7
Enforcement-related samples 73
Centrally-authorised medicinal products* 20
Mutual recognition medicinal products* 27
Microbiological Analysis:
nationally authorised medicinal products 2
Total 225
* Note: These products were sampled as part of the IMB’s participation 
in various EU Market Surveillance programmes. 
Principal findings from Analytical Testing
Two out-of-specification results were obtained during 
testing of authorised medicinal products. One related to 
non-compliance with the assay specification where it was 
found that the assay method used by the manufacturer 
underestimated the amount of active substance present 
in a tablet formulation. The second product was out-of-
specification with respect to its dissolution specification. 
Each of these issues was followed up with the companies 
concerned.
409 medicinal or other products were tested 
or examined via the sampling and analysis 
programme
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Packaging and Labelling Examination Activities
Items that are examined in this area include package 
leaflets, the labelling of product containers, summaries of 
product characteristics and parallel-imported medicinal 
products. 
One hundred and eighty four authorised medicinal and 
other products were sampled, including 25 parallel-
imported medicinal products. The latter products 
were checked for the presence of patient warnings or 
other safety information on the package leaflets, for 
the integrity and quality of their packaging (and over-
labelling), and for the quality and accuracy of the Braille 
text on the outer cartons. 
The table below provides information on the types of 
checks that were performed.
Description of the Packaging  Number of 
and Labelling Checks performed  samples
Compliance status of the packaging  
and labelling with the Marketing Authorisation 52
Presence of key safety-related and  
other information on Package Leaflets  
and product labelling 28
Presence of the correct legal classification for the 
method of sale of the product  21
Quality of the medicinal product packaging  
and over-labelling, if present 22
Braille compliance 34
Packaging and labelling of Medicinal Products 
associated with Quality Defects and/or  
Product Recall issues 7
Packaging and labelling of Medicinal Products 
associated with Classification Committee work 18
Other packaging and labelling checks 2
Total 84
Principal findings from examination of Packaging and 
Labelling
Twelve medicinal products were found not to contain 
the most up-to-date warnings on the product labelling/ 
package leaflet, five were found not to contain the most 
recently approved package leaflet, and two were found 
to be missing the required parallel product authorisation 
number on their secondary packaging. The outer carton 
used on two was determined to be of unacceptable 
quality, and for one product, it was found that the primary 
packaging rendered it difficult for the patient to remove 
the product.
Participation in European Market Surveillance Activities
The Market Compliance section participated actively 
in several EU co-ordinated surveillance programmes, 
including those for centrally-authorised, mutual 
recognition and decentralised products. The IMB sampled 
11 batches of centrally-authorised products from the 
Irish marketplace for analytical testing in other Official 
Medicines Control Laboratories (OMCLs), and the IMB’s 
OMCL analysed a total of nine batches of centrally-
authorised products that had been sampled from other 
Member States. (This represents a substantial increase on 
2007 figures, i.e. four products tested in Ireland, and five 
sampled here.)
The IMB also sampled 27 mutual recognition and 
decentralised products from the Irish marketplace for 
analytical testing at the Irish OMCL or other Member State 
OMCLs. This represents a significant increase from 13 
products sampled in 2007.
Participation in these European surveillance programmes 
gives the IMB access to a wide range of analytical expertise 
and testing competencies; it reduces duplication in 
surveillance activities across Europe; and it allows the 
IMB to benefit from a large body of surveillance data. 
Approximately 21% of the IMB’s analytical work was in 
these areas, representing a high degree of collaboration 
with other EU Member States and their OMCLs. The IMB 
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continued to be represented on the advisory group of the 
general OMCL network.
A significant number (23) of deficiencies were identified in 
analytical methods used by product manufacturers. These 
deficiencies related to nine authorised medicinal products, 
one medicinal product manufactured in Ireland for 
export-only, and four active substances. The deficiencies 
included: 
• poorly-described analytical methods, and 
• a lack of appropriate instructions for calculations in 
several methods. 
In relation to Braille, eight non-compliances were also 
identified in the text on the outer cartons of seven 
different products. These included dot height being too 
low resulting in problems reading the Braille; use of an 
incorrect Braille symbol; and the absence of a required 
Braille space cell. In addition, the Braille declarations 
submitted to the IMB by two marketing authorisation 
holders were not in compliance with the Braille text on the 
medicinal product outer carton. 
All of the above out-of-specification test results and 
method deficiency issues were followed up with the 
companies concerned, to ensure that the issues identified 
were corrected.
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Quality Defect And Recall Programme 
The quality defect and recall programme investigates, on 
a risk-basis, reports of suspected quality defects in both 
human and veterinary medicinal products, and in their 
related active substances. A total of 555 quality defects in 
human and veterinary medicinal products were reported 
to, or identified by, the Market Compliance section. This 
represents a 16% increase over 2007 figures. Factors that 
contributed to this increase included promotional work 
carried out by the section in relation to quality defect 
reporting at pharmacy level, and the introduction of an 
online quality defect reporting facility in late 2007. 
Five hundred and nineteen reports concerned medicinal 
products for human use, and 36 concerned veterinary 
medicinal products. The classifications of defects in 2008, 
along with the figures for previous years, are shown in the 
table below. 
Year 2002 2003 2004 2005 2006 2007 2008
Critical Quality Defects 6 39 50 66 84 173 127
Major Quality Defects 86 147 167 199 238 216 300
Minor Quality Defects 28 102 80 40 40 80 105
number of Quality Defect Reports not Justified 5 10 13 22 9 4 23
Total Number Quality Defects Reported 
/Identified for the Year 25 298 30 327 37 473 555
A total of 555 quality defects in human and 
veterinary medicinal products were reported to, 
or identified by, the Market Compliance section
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Of the 555 cases, 431 were determined to be affecting 
Ireland, meaning that the defective batch or batches were 
either on the Irish market and/or were manufactured in 
Ireland. 
The above table illustrates the steady increase in the 
volume of serious (i.e. major and critical) reports over 
recent years. These, at 427, accounted for 77% of all 
reported quality defects in 2008. There was, however, a 
decrease in the number of critical quality defect reports 
in 2008 compared with 2007 figures. A number of 
factors contributed to this, but the largest was the sharp 
reduction (of 34%) in the number of quality-related Rapid 
Alert communications received by the IMB from other 
Competent Authorities. 
Of the 127 critical reports, 58 directly affected Ireland, of 
which 51 concerned medicinal products for human use 
and seven concerned medicinal products for veterinary 
use. 
Of the remaining critical reports, 57 did not directly affect 
Ireland, and were received mainly from other Competent 
Authorities through the Rapid Alert notification system. 
For the 12 other cases, it was not possible to conclusively 
determine whether these reports related to products that 
were on the Irish market or not. None of these products 
was authorised and all were distributed via unauthorised 
supply routes (such as the internet). 
The table below shows the areas where quality defects 
occurred in 2008, with 38% of the total number 
concerning packaging and/or labelling issues. This increase 
was mainly due to non-compliances in the packaging 
and/or labelling of parallel imported medicinal products, 
and also in certain medicinal products missing key safety-
related information in their packs. Particulate and other 
product contamination issues were large contributors 
to the total, as were issues involving a lack of sterility 
assurance and stability. 
Areas of Quality Defects for 2008 Quality Defects Quality Defects  Quality Defects  
 in Human  in Veterinary in Human & 
 Medicines Medicines Veterinary Medicines 
 % % %
Packaging and/or Labelling  38% 44% 38%
Stability  10% 0% 9%
non-Compliance with PA/VPA  7.5% 2.8% 7.2%
Lack of Sterility Assurance, GMP non-Compliance,  
and other Product Safety-related  8.3% 17% 8.9%
non-Compliance with Specification  5.6% 8.3% 5.8%
non-Adherence to Cold Chain Requirements 1.7% 0% 1.6%
Microbial, Chemical or Particulate Product Contamination  12% 8.3% 12%
Product Mix-up  3.3% 0% 3.1%
unauthorised Product  3.7% 8.3% 4.0%
Lack of Therapeutic Efficacy  0.2% 5.6% 0.5%
Damaged Product  2.7% 0% 2.5%
Potential Counterfeit  1% 0% 0.9%
Product usage  4% 0% 4%
Other  2.7% 5.6% 2.9%
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Sources of Human Medicinal Product Quality 
Defect Reports
Sources of Veterinary Medicinal Product Quality 
Defect Reports
There was a significant increase in the level of reporting 
of quality defects in medicinal products for human use 
by community and hospital pharmacists. This is seen 
as a positive development, as the level of quality defect 
reporting by this sector in previous years had been 
decreasing. The increase was assisted by the publication 
of an IMB article on quality defect reporting in the Irish 
Pharmacy Journal in March. The availability of online 
reporting was also probably a factor in these increases. 
A number of quality defects were identified during IMB 
inspections, and during market surveillance activities 
carried out by the Market Compliance Section. 
One hundred and three quality defect and recall 
notifications were received from Competent Authorities 
and Official Medicines Control Laboratories in other 
countries. Each of these was investigated to establish if the 
report had any potential implications for the Irish market. 
Recalls of Human and Veterinary Medicinal Products 
The recall from the Irish marketplace of a batch or a 
number of batches of a medicinal product occurred in 
approximately 26% of the quality defect cases in 2008. 
This is broadly comparable to the 2007 figure (22%). 
A total of 141 recalls of medicinal products were requested 
and overseen by the IMB; this represents a significant 
increase (46%) over 2007 figures; 128 related to human 
medicinal products, and 13 related to veterinary medicinal 
products. 
As the tables on the following page indicate, packaging 
and labelling issues (particularly with regard to parallel-
imported medicinal products) accounted for the majority 
of recalls. The distribution of unauthorised products by 
Irish wholesalers was also a major contributor, and three 
‘for-cause’ inspections were carried out to follow-up on 
these issues. 
IMB Staﬀ Members 25%
Physicians and Nurses 1%
Community Pharmacists 5%
Hospital Pharmacists 9%
Companies (Manufacturers, Distributors 
and/or PA Holders) 34%
Patients and/or Members of the Public 1%
Competitor
Companies 1%
Other competent
authorities 24%
IMB staﬀ members 19%
Department of  Agriculture, 
Fisheries & Food 22%
Companies (Manufacturers, Distributors 
and/or VPA Holders) 37%
Other competent authorities 22%
A total of 4 recalls of medicinal products 
were requested and overseen by the IMB; this 
represents a significant increase of 46% over 
2007 figures
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Human Medicinal Product Recalls from the Irish Market
Year 2005 2006 2007 2008
Packaging and / or Labelling  10 14 21 73
Stability  7 3 3 6
non-compliance with MA  6 0 5 3
unfavourable Risk/Benefit Ratio and various other Product Safety Concerns 13 8 13 5
non-compliance with Specification  3 4 1 9
non-adherence to Cold Chain  1 0 19 1
Microbial, Chemical & Particulate Contamination  1 4 12 5
Product Mix-up  3 3 1 3
unauthorised Product  20 11 4 15
Lack of Therapeutic Efficacy  0 0 3 0
Damaged Product  * 3 1 1
Product usage  * 5 1 0
Other  4 1 4 7
Total  68 56 88 128
* These are new categories from 2006 onwards. 
Veterinary Medicinal Product Recalls from the Irish Market
Year 2005 2006 2007 2008
Packaging and / or Labelling  3 1 2 10
Stability  0 1 0 0
non-compliance with VPA  0 0 0 0
Sterility Assurance and various other Product Safety Concerns 1 0 0 0
non-compliance with Specification  1 0 2 0
Particulate or other Contamination  0 0 0 0
Product Mix-up  0 0 0 0
unauthorised Product  1 0 4 2
Other  0 0 1 1
Total  6 2 9 13
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Regulatory Compliance Inspections 
In 2007, a pilot programme of regulatory compliance 
inspections was developed and run by the Market 
Compliance section. The purpose was to facilitate the 
development of a formal programme for inspecting the 
premises of marketing authorisation holder companies, 
on a risk-basis. In 2008, three such inspections were 
carried out. The areas of activity in those companies that 
have a high potential to impact upon the quality, safety 
and safe use of medicinal products were focussed on. 
These included advertising and promotional activities, 
management of registered product information, 
management and communication of regulatory 
commitments and regulatory changes, implementation 
of changes to product information and product labelling 
in the marketplace, and the provision of a medical 
information services for healthcare professionals. 
Compliance issues that come to light during these 
inspections have been fed back, in anonymised form, to 
MA holders with the intention of improving compliance 
with legislative requirements. 
Exempt Medicinal Products
In 2006, the Department of Health and Children 
commissioned the IMB to carry out a research project 
into the importation, supply and use of unauthorised 
medicinal products in Ireland. An extensive programme 
of research and stakeholder consultation followed. The 
final report was approved by the Board of the IMB and 
forwarded to the Department of Health and Children 
during 2008. 
The Medicinal Products Regulations of 2007 permit 
wholesalers and manufacturers to source exempt 
medicinal products in response to an order from a 
practitioner for individual patients under his/her care. 
Since January 2008, wholesalers and manufacturers have 
been obliged, within seven days of sourcing unauthorised 
medicinal products, to notify certain information to the 
IMB. The main purpose of receiving such information is to 
facilitate the effective recall of any defective unauthorised 
medicinal products from the Irish market.
The IMB put in place an online notification system 
for receipt of information from wholesalers and 
manufacturers. This became operational on 18 February. 
At the end of 2008, a total of 28 companies had 
registered with the IMB to use this notification system, 
and of those, 24 had imported and supplied exempt 
products.
Approximately 16,000 medicinal product lines 
(comprising of packs from approximately 29,000 batches) 
were notified. A ‘product line’ represents each product 
name on the list notified by a wholesaler/manufacturer 
on each occasion that a notification is made. It does not 
reflect the number of packs or the number of different 
batch numbers sourced at any one time. 
A wide range of product types has been notified, 
including oral solid dosage forms, oral liquid preparations, 
topical preparations, injectable preparations, parenteral 
nutrition preparations, suppositories and pessaries. The 
IMB is concerned by the high numbers of unauthorised 
medicinal products that are imported and supplied in 
Ireland and is working with other agencies with a view to 
reducing these. 
EnFORCEMEnT
Overview
During the reporting year the Enforcement section 
initiated 3,037 enforcement cases involving breaches of 
medicinal product legislation, compared to 1,397 cases 
initiated in 2007. This represents a year-on-year increase 
of 117% following on from a 297% increase in 2007. 
The significant increase in cases was primarily due to 
detection of illegal mail order importations of prescription 
only medicinal products. The co-operation of the 
Revenue Customs Service in facilitating this is gratefully 
acknowledged. In 583 cases where the purchaser of 
The Enforcement section saw an increase 
of 7% in the number of cases involving 
breach  of medicinal product legislation
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medicines from the internet stated the website from 
which he/she bought the product, over half (294 
websites) were found to be spurious ‘pharmacies’ most 
likely owned by a non-compliant business entity. A total of 
141 websites were located in the USA and 53 in one of the 
EU States. Many of the 583 reports concerned the same 
website. The IMB works with other agencies and internet 
service providers in seeking to stop or limit the activities of 
such websites.
During 2008 the Enforcement section detained 393,067 
units of capsules, liquids and creams compared to 
188,784 units in 2007 – an increase of 108%. Examples 
of active substances included in products detained were 
diazepam, zopiclone, sildenafil citrate, tadalafil and other 
erectile dysfunction formulations, rimonabant, finasteride, 
testosterone, amoxicillin, antibiotics, corticosteroids and 
weight-loss products.
The majority of unauthorised supplies into Ireland of 
unauthorised medicinal products originated from India, 
with the next largest group originating from China.
Medicinal products destroyed during the year in 
compliance with the Waste Management Acts 1996–2001 
amounted to 1,902 kg compared to 976 kg in 2007.
Both national and international liaison with other 
enforcement agencies in Ireland and abroad enables the 
IMB to co-operate to stem the unauthorised flow of illegal 
medicinal products and medical devices into and out of 
Ireland. During the year enforcement officers and custom 
officers carried out a joint operation in the Shannon 
region. 
Between May and December 2008, 43 packages that were 
detained on suspicion of being counterfeit were analysed 
and the results indicated that 33 were counterfeit. 
Prosecutions were initiated in the District Court in both 
Bailieborough and Dublin with a successful outcome 
in each case. On 17 October, at Bailieborough District 
Court, a group of three pharmacies, and an associated 
legal entity, pleaded guilty to breaches of the Medicinal 
Products (Licensing and Sale) Regulations, 1998, as 
amended. Fines totalling €5,000 were imposed. At 
Dublin District Court, Dolphin House the proprietor of a 
retail outlet in Dublin pleaded guilty to breaches of the 
Medicinal Products (Licensing and Sale) Regulations, 
1998, as amended, the Medicinal Products (Prescription 
and Control of Supply) Regulations, 2003, as amended 
and the Medical Preparations (Licensing of Manufacture) 
Regulations 1993, as amended. Fines totalling €600 were 
imposed. 
Analysis of Enforcement case activity
PLAnnInG
The Planning section is responsible for planning activities 
across the Compliance Department and works closely 
with the other four sections in this regard. It has a role 
in collating training and liaises with the IMB’s central 
training section. It is also responsible for reporting on all 
departmental activities.
The main focus of the Planning section relates to the 
compilation of the inspection programme. Planning was 
also involved in the co-ordination of several training and 
information sessions including the GMP Information 
Seminar which took place in October. This was attended 
by over 260 delegates from the industry.
The section also worked closely with the Information 
Technology and Change Management department on the 
development of a workflow system for Compliance. 
Import 1,056
Advertising 73
Counterfeit 33
Others 58
Retail 51
Internet 10
Wholesale 5
Mail order 1,751
During 2008 the Enforcement section detained 
393,067 units of capsules, liquids and 
creams compared to 188,784 units in 2007  
– an increase of 08%
Compliance  
(continued)
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The Information Technology & Change Management 
Department delivers a range of support services across 
the organisation. These include specialist technology and 
telecommunications services together with business skills 
focussed on delivering process improvements across the 
organisation. 
In 2008 the department provided systems support 
services to over 250 staff  on a wide range of specialised 
systems, ranging from business analysis through to 
end-user training. Support is also provided to a number 
of external bodies, including the Maltese and Norwegian 
regulatory authorities. 
CHAnGE MAnAGEMEnT 
The IMB has a well established change management 
programme with a strong focus on continuous 
improvement. The analysis and implementation of 
solutions to enhance business processes has been a 
fundamental activity within the organisation since 2003. 
In late 2007 the Board committed to developing a new 
role with a dedicated focus on safety-related issues. 
This initiative represented a signifi cant programme of 
work for the organisation during 2008. In summary, 
the existing medical devices department and human 
medicines licensing departments were analysed with a 
view to developing two alternative structures in which 
one department would focus on licensing and registration 
activities for all human products, while the second would 
focus on safety matters for human products. (‘Human 
products’ refers to both pharmaceuticals and medical 
devices.) Over the course of 2008 a comprehensive 
consultation process was undertaken, both internally 
and externally. A fi nal proposal for the new structure 
was considered and approved by the Board in November 
2008. The implementation of the new organisational 
arrangements, impacting on approximately 120 members 
of staff , is scheduled for March 2009.
Information 
Technology and 
Change Management Ms. Suzanne McDonald Director of IT & Change Management
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The announcement of the merger of the Food Safety 
Authority of Ireland, Irish Medicines Board and Office 
of Tobacco Control in the autumn of 2008 prompted a 
number of information-sharing meetings on the topic of 
technology.
TECHnOLOGy
European IT Projects
The IMB’s technology unit continues to play an active 
role at European level through its involvement in 
a range of EU Telematics projects which reflect the 
wider licensing, vigilance and compliance role of the 
IMB. The EU Telematics Programme aims to develop 
central repositories for pharmaceutical data and safety 
information, for use by healthcare professionals, patients 
and regulators. During 2008 there were nine ongoing 
projects, ranging from telecommunications (EudraNet) 
through to the safety monitoring system (EudraVigilance). 
In 2008, the IMB played an active part in the following EU 
IT projects:
• EudraVigilance (drug safety)
• EudraPharm (medicinal product information)
• EudraGMP (good manufacturing practice)
• EudraCT (clinical trials)
• EudraNet (secure network communications)
• CTS (MR/DCP tracking system)
• eSubmissions (electronic submissions)
• EU Datawarehousing /Reference Data Modelling 
• Product Information Management (PIM)
Web-Based Services
Technology also played its part in delivering 
improvements for both stakeholders and the IMB during 
2008. ‘RIO’ (the online application and tracking system 
for the pharmaceutical industry) continued to grow 
in popularity during 2008 with many new companies 
signing up to use the system. The system has also 
attracted the interest of other regulatory bodies within 
the EU, and has been well received by the pharmaceutical 
industry. A working group of IMB staff and the 
pharmaceutical industry continues to identify new and 
improved ways of using the system. At the end of 2008 
over 400 users were registered, and during the year over 
3,000 product applications were received via the system. 
We encourage the pharmaceutical industry and its agents 
to subscribe to the system and to contact us for further 
information on registration. 
The IMB website received a large number of visitors 
during 2008. Statistics show that the list of authorised 
medicinal products for human use was the most popular 
section of the website. The safety notices section of the 
site was also very busy during the year, with all notices 
now dispatched automatically to registered users. 
Individuals interested in received safety information via 
e-mail or SMS should register on the IMB website. The 
website also provides online forms to facilitate reports on 
possible adverse reactions to medicines, potential quality 
defects and incidents relating to medical devices. In 2008 
approximately 10% of adverse reaction reports were 
received via the website. Users are encouraged to register 
on the new website and to utilise the reporting forms 
wherever possible. 
Comments or suggestions for improvement to the 
website are always welcome and should be sent to 
helpdesk@imb.ie. 
Eudra Portal
EU Telematics Controlled Terminology
Reference Data Model
Eudra Services
Eudra Net, Eudra Link, Web Services, SSO
E-Sub-
mission
Eudra
pharm
Eudra
CT
Eudra
Vig.
Eudra
GMP
PIM
During the year approximately 0% of 
adverse reaction reports were received via the 
website
Information Technology and Change Management 
(continued)
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Online Web Based Reports
Training
Training is an essential part of the role of the IT & Change 
Management department. In 2008 over 90 members of 
staff received training from the department while over 150 
external users received web-based training.
Safety Solutions
In line with the organisational focus on safety-
related activities, work commenced in 2008 on the 
implementation of a new safety system. This new 
system provides enhanced features and supports secure 
electronic reporting at both national and international 
level. Significant changes have taken place in the 
area of pharmacovigilance over the past number of 
years, particularly in relation to E2B reporting via the 
EudraVigilance system at the European Medicines Agency. 
The introduction of a more sophisticated support and 
monitoring system is an essential tool in the recording, 
analysis and monitoring of safety information for 
pharmaceuticals. The new system is sufficiently flexible to 
handle medical device data and its use may therefore be 
extended to managing additional vigilance information 
within the next few years.
Adverse reaction 
Pharmaceutical
/tissues & cells 291
Quality defect report
Pharmaceutical 64
Adverse event 
medical device 53
Licensing and Registration Solutions
The IMB continues to develop workflow-based solutions 
to assist in its operations. To date, the organisation 
has implemented workflow across both the veterinary 
and human medicines areas, and is currently working 
on the implementation of a similar solution within 
the Compliance department in the areas of inspection, 
licensing and market compliance. Core systems are 
continually upgraded throughout the year to reflect the 
evolving regulatory environment, and also to deliver 
further improvements. In 2008 both the human and 
veterinary medicines systems were upgraded and work is 
already underway for 2009 to reflect changes resulting 
from the introduction of revised European pharmaceutical 
legislation.
Technology-based solutions are also in place to support 
the registration and assessment of medical devices, while 
electronic reporting systems were deployed in early 2008 
to support exempt medical product notifications to the 
IMB. Over 16,000 product lines were reported via the 
online system in 2008.
Over 90 members of staff received training 
from the department while over 50 external 
users received web-based training in 2008
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BORDERLInE PRODuCT CLASSIFICATIOn
The IMB provides a service to stakeholders to assist 
in clarifying which products should be categorised as 
medicinal products and medical devices and thereby fall 
under the remit of IMB from a regulatory perspective and 
to distinguish such products from other products which 
are outside the scope of IMB’s remit. Queries routinely 
are received in regard to human medicinal products, 
veterinary medicinal products and medical devices and 
in each of the three areas, relevant personnel within the 
organisation have provided on request, an IMB decision as 
to the status of a given product. This service in each of the 
three areas has been standardised under the IMB Quality 
Management System. 
Human Medicines
A classifi cation service is operated for products which are 
on the borderline of human medicines and other products 
such as food supplements, cosmetics and medical 
devices. Requests for classifi cation whether external or 
internal are ultimately presented to an internal multi-
disciplinary human medicines Classifi cation Committee 
which meets once a month. The outcome of the decision 
is conveyed promptly to the enquirers and in turn is 
accompanied by a recommendation for any action 
arising depending upon the circumstances. In the event 
of an appeal to the Classifi cation Committee decision, 
the matter will normally be referred to the Advisory 
Committee on Human Medicines for arbitration. Full 
details of the procedure can be found in the Guide to the 
Defi nition of a Medicinal Product which can be found on 
the IMB website. This was revised in 2008 following the 
implementation of the new legislation relating to human 
medicinal products, adopted in Ireland in 2007.
Chief Executive’s 
Office
The IMB Classifi cation Committee (human 
medicines) considered a total of 80 new 
products in 2008
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Source of Medical Device Classification Queries
QuALITy MAnAGEMEnT
Implementation of the IMB-wide quality 
management system
During the year, 486 requests for documents were made 
under the quality management system and 425 were 
approved or withdrawn. Of the total number of requests, 
257 were requests for new documents, 229 for revisions 
of documents and 13 for withdrawals. The graph below 
shows the relevant figures for the past three years. The 
increase in the number of documents in revision reflects 
the growing maturity of the system.
Document control requests by year
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The IMB Classification Committee (human medicines) 
met nine times in 2008 and considered a total of 80 new 
products. In addition, there were 27 products revisited 
from pre-2008. The committee consists of appropriately 
experienced IMB staff from Human Medicines, 
Compliance and Medical Device Departments and is 
chaired by Dr. J.M. Morris, Senior Scientific Advisor.
During 2008, the majority of the applications were 
internal applications (56) emanating mainly from the 
Compliance Department, with 24 external applications.
The Classification Committee continues to work 
closely with the IMB Compliance department’s Market 
Compliance section, which is represented on the 
committee, and with the Enforcement section. Externally, 
there is also a very close working relationship with the 
Food Safety Authority of Ireland and a number of referrals 
were made in both directions during the course of 2008.
The Classification Committee also engaged in regular 
dialogue with the Department of Health and Children and 
also with the Advertising Standards Authority of Ireland. 
Human Medicines – Source of Classification 
Queries
Internal applications 
52%
Revisited 26%
External applications 
22%
Dr. Caitríona Fisher  
Quality Manager
Dr. Mike Morris  
Senior Scientific Advisor
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Implementation status 31 December 2008
Progress towards completion increased substantially in 
2008 as shown in the graph below, due to an increase in 
resources devoted to this work, both within departments 
and within the Chief Executive’s Office where the number 
of staff within the QMS section increased to six during 
2008.
Total quality system complete by year
At the end of the year, there were 587 documents 
approved within the system. The distribution of approved 
documents by type is shown in the chart below. Of 
interest are the large number of guidelines, reflecting the 
organisation’s provision of technical guidance for both 
stakeholders and staff, and the large number of forms 
(51%) reflecting record-keeping requirements.
Approved documents by type
Development of the quality system and migration of 
current department quality systems to the organisation’s 
system continued during 2008. At the end of the year, 
67% of the estimated total implementation has been 
achieved or was in progress, as shown in the graph below.
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Chief Executive’s Office  
(continued)
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Internal audit
Eleven audits were carried out in 2008, on 14 processes 
(up from 7 in 2007). As in 2007, the objective of internal 
audits was conformance to procedures, with auditors from 
the QMS section and from IMB departments reviewing 
procedures against the approved SOPs and checking for 
evidence of training. The audits included authorisation 
processes for both human and veterinary medicines: 
quality procedures relating to the control of documents, 
internal audits and non-conformances: and an audit of 
the service charter. At the end of the year, all audits were 
closed out except for two where the target completion 
date for non-conformances is March 2009. 
Updates on the quality system were communicated to 
staff on an ongoing basis and induction training was 
carried out for all new staff. 
Benchmarking of European Medicines Agencies 
The IMB co-chairs and participates in the Heads of 
Medicines Agencies Steering Group for the second cycle of 
benchmarking of European medicines agencies (BEMA). 
The process consists of self-assessment by each agency 
against agreed indicators of best practice, followed by 
an assessment of the agency by assessors from other 
European agencies who visit the agency, interview staff 
and review evidence to support the maturity rating 
assigned. During the early part of 2008, extensive training 
was given to EU assessors who have volunteered to 
participate in this second cycle, including case study review 
and rating to ensure consistency of approach. In June, 
the assessment visits began and by the end of the year, 
six visits had been completed. One member of staff from 
the QMS section participated in these visits. The visits will 
continue through 2009 and 2010.
Working Group of Quality Managers
In 2008, the Heads of Medicines Agencies established 
a working group for the quality managers in medicines 
agencies across the EU Member States. The group’s 
mandate is to improve the exchange of quality 
management expertise and to contribute towards the 
development of best practices for quality management. 
The group’s first meeting was held in Dublin in May, 
hosted by the IMB and chaired by the IMB’s quality 
manager, with a second meeting under the French 
Presidency in Paris. 
Joint Audit Programme for GMP related Activities
During July activities relating to GMP inspection, licensing, 
marketing compliance and enforcement (some aspects) 
were audited by a team of three GMP inspectors from 
Spain and Germany (2). This was part of the Heads of 
Medicines Agencies Joint Audit Programme.
The audit team was satisfied with the overall level of 
compliance and the audit was closed out before year end.
 internal audits were carried out in 2008, on 
4 processes (up from 7 in 2007)
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Finance and 
Corporate Affairs
The finance and Corporate Aff airs department delivers a 
number of key services areas to the organisation. 
These include:
• Managing and safeguarding the fi nances of the IMB.
• Developing and managing the human resource needs 
of the organisation.
• Providing secretarial support to the Board and 
Committees and ensuring adherence to best practice 
in the area of corporate governance.
• Managing the building and accommodation 
requirements of the IMB.
• Providing infrastructure requirements for staff  and 
visitors from cleaning, reception, canteen, travel 
service through to library services.
• Managing the Freedom of Information obligations.
• Managing the legal issues for the IMB.
2008 was another challenging and busy year for the 
department and some of the highlights are outlined 
below.
FInAnCE 
As outlined in the fi nancial statements, the IMB’s 
fi nances remained stable. The fi nance section continued 
to successfully manage the high volumes of work while 
maintaining high standards of internal control. To further 
increase effi  ciency and make a contribution towards a 
greener environment, the payroll section introduced 
electronic payslips during the year, replacing the previously 
used paper versions. In 2008 internal auditors reviewed 
fi nancial management and information systems 
with a satisfactory outcome. They also reviewed their 
recommendations from their audit in 2006 of debtors and 
banking and fi nance. All procedures were carried out using 
standard operating procedures under the IMB’s quality 
management system which has added great value to the 
operation of the department.
The fi nance section continued to successfully 
manage the high volumes of work while 
maintaining high standards of internal control
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CORPORATE SERVICES
2008 was a busy year for Corporate Services as the 
increases in operations and staff in all the other 
departments increase the level of services provided. 
In recognition of environmental issues Corporate 
Services facilitated the setting up of a ’green team‘ which 
has looked at all consumables in the organisation and 
developed plans for reducing consumption and cost.
The IMB held four information days in 2008 and there 
was a very good turnout to each of these days. The IMB 
also hosted a European Pharmacopeia meeting in April 
and on behalf of the Slovenia Presidency hosted the Third 
Working Group of European Medicines Enforcement 
Officers (WGEO), Heads of Medicines Agency meeting in 
April 2008.
The IMB published three Medicinal Products Newsletters 
in 2008, issue numbers 29, 30 and 31. The newsletters 
cover a wide range of topics such as electronic reporting 
for adverse reactions, GMP updates, veterinary 
pharmacovigilance, Braille and patient-accessible leaflets 
and many more items including the list of all marketing 
authorisations issued. The IMB newsletters are circulated 
via e-mail; if you wish to be added to the mailing list 
please e-mail foi@imb.ie. 
There was a large number of Freedom of Information 
Act requests in 2008. The IMB received 19 non personal 
requests and two personal requests for information. The 
outcome of these requests is outlined below:
Request outcome
number of FOI requests received 21
Granted/ Part Granted  17
Refused 4
Withdrawn/ Handled outside FOI Act –
Internal Reviews 2
Appeals to the Information Commissioner –
BuILDInGS
In 2008 the IMB successfully sought and was granted 
planning permission to add an additional two floors to 
Kevin O’Malley House. Given the location of the building 
this represents an uplift in the value of the building and 
provides an opportunity to acquire additional office space 
at a very reasonable cost. As the business of the IMB has 
expanded considerably over the last three years this will 
help to meet the future accommodation needs of the 
organisation.
In 2008 we also carried out a review of our utility costs to 
ensure that our service providers are delivering value to 
the organisation.
HuMAn RESOuRCES
The organisation headcount increased in 2008 to 252 
staff, representing a whole-time equivalent number of 
240.6 and is broken down as follows:
Number of staff Male Female Total
Part-time 2 22 24
Full-time 66 162 228
Significant developments during the year included:
• Board approval of the need for representation of the 
Human Resources function at executive level and 
the creation of a separate department to commence 
operations in 2009.
• Provision of coaching and HR support for line 
management arising from the internal reorganisation 
of departments
• Successful outcome of internal QMS audit of 
recruitment procedures
• Review of activities of the training section with a focus 
on improving training needs identification across the 
organisation and preparation for the development of 
electronic recording during 2009.
• Staff survey completed in line with obligations under 
the Disability Act; target of 3% exceeded.
• Development of recruitment module on the HR IT 
system resulting in a more effective logging and 
tracking of recruitment applications
• An increase in staff numbers undertaking further 
education (from 8.9% to 9.3%)
• Average number of training days per individual in 2008 
was three. 
In 2008 the IMB successfully sought and 
was granted planning permission to add an 
additional two floors to Kevin O’Malley House
Ms. Rita Purcell  
Director of Finance and Corporate Affairs
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Corporate Governance
The Irish Medicines Board (the IMB) was established under the terms of the Irish Medicines Board Act, 1995, and is 
governed by a Board which was appointed by the Minister for Health & Children. The Board of the IMB (the Board) consists 
of a chairman and seven unremunerated non executive members.
The IMB is committed to the highest standards of Corporate Governance and has implemented the Department of Finance 
“Code of Practice for the Governance of State Bodies”. This Code of Practice, which was issued to the Irish Medicines 
Board in January 2002, incorporates many of the principles under which the IMB operates, taking account of the size and 
legal nature of the organisation. The IMB has in place an extensive Code of Conduct for all staff, committees and Board 
members. The IMB applies the highest standards of disclosure and transparency in respect of interests held by staff, 
committees and Board members.
Audit Committee
The IMB has an audit committee comprising two Board members, which met on three occasions during 2008. This 
committee is responsible for reviewing internal control matters, together with any other issues raised by the external 
auditors, the Board or management. The external auditor meets annually with the committee to brief them on the 
outcome of the external audit. In 2005 the IMB appointed Crowleys DFK as internal auditor to the Board under a three-year 
contract. During 2008 the internal auditors reviewed the areas of financial management, information systems, debtors and 
banking and reported their findings to the audit committee. The audit committee has also been involved with the review of 
the quality systems as described below.
Quality Systems
During 2008, the finance section of the IMB continued the process of implementing and reviewing standard operating 
procedures ( SOPs ) under the quality management system. This process involved a critical review and analysis of internal 
controls and processes throughout the section with particular emphasis on risk management. This system now underpins 
the internal control environment and feeds into the internal audit process and ultimately into the audit committee.
Remuneration Policy - Board Members and Executive Directors
Remuneration and travel expenses paid to Board members are disclosed in note 17 to the financial statements. The 
Chairman receives remuneration as directed by the Minister for Health and Children in accordance with the Irish Medicines 
Board Act, 1995. Other Board members receive travel expenses in accordance with circulars issued by the Department of 
Health and Children. The Chief Executive is remunerated in accordance with guidelines issued from Government and other 
Executive Directors are paid in accordance with Department of Health and Children pay scales. 
Remuneration Committee
The IMB has established a remuneration committee as a sub-committee of the Board to review the remuneration of the 
Chief Executive in accordance with guidelines issued by the Department of Finance and the Department of Health & Children. 
The Chief Executive’s remuneration is disclosed net of superannuation contributions in note 18 to the Financial Statements.
Internal Control
The Board is responsible for the IMB’s systems of internal control. Such systems can only provide reasonable and not 
absolute assurance against material misstatement or loss. The systems of internal controls in use in the Irish Medicines 
Board are described more fully in the Chairman’s report on page 52.
Going Concern
The Board has a reasonable expectation, at the time of approving the financial statements, that the IMB has adequate 
resources to continue its operations. Government have announced plans for the merger of the IMB, the Food Safety 
Authority of Ireland and the Office of Tobacco Control in 2011. The merger would result in the assets and liabilities of the 
IMB being transferred to this new organisation. For this reason, the Board continues to adopt the going concern basis in 
preparing the financial statements.
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Report of the Chairman of the Irish Medicines oard 
regarding the assessment of internal financial controls of a State body for the year ended 31st December 2008
1. I, as Chairman, acknowledge that the Board is responsible for the body’s system of internal financial control.
2. The IMB system of internal control can provide only reasonable and not absolute assurance against material error, 
misstatement or loss.
3. The Board confirms that there is an ongoing process for identifying, evaluating and managing the significant risks faced 
by the IMB. This process is regularly reviewed by the Board via the report of the Chief Executive.
 Management are responsible for the identification and evaluation of significant risks applicable to their areas of business 
together with the design and operation of suitable internal controls. These risks are assessed on a continuing basis and 
may be associated with a variety of internal or external sources including control breakdowns, disruption in information 
systems, natural catastrophe and regulatory requirements.
 Management reports fortnightly on operational issues and risks and how they are managed to the Management 
Committee. The Management Committee’s role in this regard is to review on behalf of the Board the key risks inherent 
in the affairs of the IMB and the system of actions necessary to manage such risks and to present their findings on 
significant matters via the Chief Executive to the Board.
 The Chief Executive reports to the Board on behalf of the executive management on significant changes in the work 
of the IMB and on the external environment, which affects significant risks. The Director of Finance and Corporate 
Affairs provides the Board with monthly financial information, which includes key performance indicators. Where areas 
for improvement in the system are identified the Board considers the recommendations made by the Management 
Committee.
 An appropriate control framework is in place with clearly defined matters which are reserved for Board approval only or, 
as delegated by the Board, for appropriate Executive approval. The Board has delegated the day-to-day management 
of the IMB and established appropriate limits for expenditure authorisation to the Executive. The Chief Executive is 
responsible for implementation of internal controls, including internal financial control.
 The system of internal financial control is monitored in general by the processes outlined above. In addition, the Audit 
Committee of the Board reviews specific areas of internal control as part of their terms of reference.
4. The Audit Committee of the Board have satisfactorily reviewed the effectiveness of the system of internal control on 
behalf of the Board. The Audit Committee of the Board carried out a formal review of these systems in respect of 2008 
at its meeting on 29th April 2009.
 
Pat O’Mahony 
Chairman
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Statement of oard Members’ Responsibilities
The Board is required by the Irish Medicines Board Act, 1995 to prepare financial statements for each financial year which 
give a true and fair view of the state of affairs of the Irish Medicines Board and of its surplus or deficit for that period.
In preparing those statements the Board is required to:
• select suitable accounting policies and apply them consistently
• make judgements and estimates that are reasonable and prudent
• disclose and explain any material departures from applicable accounting standards, and
• prepare the financial statements on a going concern basis unless it is inappropriate to presume that the Irish Medicines 
Board will continue in existence.
The Board is responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the 
financial position of the Irish Medicines Board and which enable it to ensure that the financial statements comply with 
the IMB Act and with accounting standards generally accepted in Ireland. It is also responsible for safeguarding the assets 
of the Irish Medicines Board and hence for taking reasonable steps for the prevention and detection of fraud and other 
irregularities.
 
On behalf of the Board
 
Pat O’Mahony Maureen Windle 
Chairman Board Member
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Report of the Comptroller and Auditor General 
for presentation to the Houses of the Oireachtas
I have audited the financial statements of the Irish Medicines Board for the year ended 31 December 2008 under Section 18 
of the Irish Medicines Board Act, 1995.
The financial statements, which have been prepared under the accounting policies set out therein, comprise the Accounting 
Policies, the Statement of Income and Expenditure, the Statement of Total Recognised Gains and Losses, the Balance Sheet, 
the Cash Flow Statement and the related notes.
Respective Responsibilities of the Board and the Comptroller and Auditor General
The Irish Medicines Board is responsible for preparing the financial statements in accordance with the Irish Medicines Board 
Act, 1995, and for ensuring the regularity of transactions. The Board prepares the financial statements in accordance with 
Generally Accepted Accounting Practice in Ireland as modified by the directions of the Minister for Health and Children in 
relation to accounting for superannuation costs. The accounting responsibilities of the Board Members are set out in the 
Statement of Board Members’ Responsibilities. 
My responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and 
International Standards on Auditing (UK and Ireland).
I report my opinion as to whether the financial statements give a true and fair view, in accordance with Generally Accepted 
Accounting Practice in Ireland. I also report whether in my opinion proper books of account have been kept. In addition, I 
state whether the financial statements are in agreement with the books of account.
I report any material instance where moneys have not been applied for the purposes intended or where the transactions do 
not conform to the authorities governing them.
I also report if I have not obtained all the information and explanations necessary for the purposes of my audit.
I review whether the Statement on Internal Financial Control reflects the Board’s compliance with the Code of Practice for 
the Governance of State Bodies and report any material instance where it does not do so, or if the statement is misleading 
or inconsistent with other information of which I am aware from my audit of the financial statements. I am not required to 
consider whether the Statement on Internal Financial Control covers all financial risks and controls, or to form an opinion 
on the effectiveness of the risk and control procedures.
I read other information contained in the Annual Report, and consider whether it is consistent with the audited financial 
statements. I consider the implications for my report if I become aware of any apparent misstatements or material 
inconsistencies with the financial statements.
Basis of Audit Opinion
In the exercise of my function as Comptroller and Auditor General, I conducted my audit of the financial statements in 
accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board and by 
reference to the special considerations which attach to State bodies in relation to their management and operation. An 
audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures and regularity of the 
financial transactions included in the financial statements. It also includes an assessment of the significant estimates and 
judgments made in the preparation of the financial statements, and of whether the accounting policies are appropriate to 
the Board’s circumstances, consistently applied and adequately disclosed.
I planned and performed my audit so as to obtain all the information and explanations that I considered necessary in order 
to provide me with sufficient evidence to give reasonable assurance that the financial statements are free from material 
misstatement, whether caused by fraud or other irregularity or error. In forming my opinion I also evaluated the overall 
adequacy of the presentation of information in the financial statements.
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Opinion
In compliance with the directions of the Minister for Health and Children, the Board recognises the costs of superannuation 
entitlements only as they become payable. This basis of accounting does not comply with Financial Reporting Standard 17 
which requires such costs to be recognised in the year the entitlements are earned. 
Except for the non-recognition of the Board’s superannuation costs and liabilities in accordance with Financial Reporting 
Standard 17, the financial statements give a true and fair view, in accordance with Generally Accepted Accounting Principles 
in Ireland, of the state of the Board’s affairs at 31 December 2008 and of its income and expenditure for the year then 
ended.
In my opinion, proper books of account have been kept by the Board. The financial statements are in agreement with the 
books of account.
Gerard Smyth 
For and on behalf of the Comptroller and Auditor General 
31 August 2009
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Accounting Policies
Historical Cost Convention
The Financial Statements are prepared in accordance with generally accepted accounting principles under the historical cost 
convention and comply with the financial reporting standards of the Accounting Standards Board, with the exception of 
superannuation – see note below.
Income Recognition
Income is recognised in the financial statements on the following basis:
• In the case of applications for product authorisations (new applications, variations to existing authorisations, or 
transfers) and clinical trial applications, income is recognised in the financial statements when a valid application form is 
received. 
• In the case of wholesale and manufacturing licences and maintenance of product authorisations, fees are payable 
annually and a full year’s income is accrued in each financial year.
Expenditure Recognition
Expenditure is recognised in the financial statements on an accruals basis as it is incurred.
Reporting Currency and Currency Translation
The financial statements are prepared in euros.
Transactions in currencies other than euro are recorded at the rates ruling at the date of the transactions or at a contracted 
date. Monetary assets and liabilities are translated into euro at the balance sheet date or at a contracted date. Exchange 
differences are dealt with in the income and expenditure account. 
Tangible Assets
Tangible Assets excluding Premises
Tangible assets excluding premises are stated at cost less accumulated depreciation. Depreciation is calculated in order 
to write off the cost of tangible assets to their estimated residual values over their estimated useful lives by equal annual 
instalments.
The estimated useful lives of tangible assets by reference to which depreciation has been calculated are as follows:
Leasehold Property : Unexpired portion  
 of the lease
Fixtures and Fittings :  5 years
Computer Equipment :  3 years
Improvements to Premises : 10 years
Premises
The IMB purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2 on 22 December 2004. 
The value capitalised was equal to the purchase price plus those costs directly attributable to bringing the asset into use.
No depreciation has been calculated on the value of premises, as the remaining useful economic life is estimated to be 
greater than 50 years.
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Taxation
The Irish Medicines Board is exempt from liability to Corporation Tax under Section 32 of the Finance Act, 1994.
Debtors
Known bad debts are written off and specific provision is made for any amount the collection of which is considered 
doubtful. 
Superannuation
The superannuation scheme operated by the Irish Medicines Board is in accordance with the Local Government 
(Superannuation Revision) (Consolidation) Scheme, 1986. It is an unfunded statutory scheme and benefits are met from 
current income as they arise.
The charge to salaries and wages is stated gross of superannuation deductions of €637,517 (2007 - €521,844 ). The surplus 
for the year on page 58 is then shown both before and after superannuation transactions for the year. The income and 
expenditure reserve on the balance sheet is split between retained reserves and superannuation reserves in note 11. 
By direction of the Minister for Health & Children, the provisions of FRS 17 are not being complied with. 
Provisions
A provision is recognised when the IMB has a present obligation as a result of a past event, it is probable that this will be 
settled at a cost to the IMB and a reliable estimate can be made of the amount of the obligation.
Library
No value has been placed on the books, audio-visual resources and electronic databases in the library. Expenditure on these 
items is written off in the year in which it is incurred.
Leases
All leases are treated as operating leases and the rentals thereunder are charged to the Income and Expenditure account on 
a straight line basis over the lease period.
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Statement of Income and Expenditure
For the year ended 31 December 2008
  Note  2008  2007 
   €  €
Fee Income  2  18,704,256   17,239,949 
Other Income 3  5,220,407   5,073,029 
    23,924,663   22,312,978 
Salaries and Wages 4  15,255,687   13,239,398 
Other Operating Costs 5  5,888,006   5,951,791 
Depreciation 1  1,606,304   1,247,081 
    22,749,997   20,438,270 
Surplus for the year before write back of Superannuation contributions   1,174,666   1,874,708 
Staff Superannuation Contributions   637,517   521,844 
Surplus for the year   1,812,183   2,396,552 
Balance brought forward   12,674,947   10,278,395 
Balance carried forward   14,487,130   12,674,947
All income and the surplus for the year arises from continuing activities.   
 
Pat O’Mahony Maureen Windle 
Chairman Board Member
The accounting policies on pages 56 to 57 and the notes on pages 62 to 69 form part of the financial statements.
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Statement of Total Recognised Gains and Losses 
For the year ended 31 December 2008
  Note  2008  2007 
   €  €
Retained Surplus For The Year   1,812,183  2,396,552
Unrealised Gains For The Year  –  – 
Total Recognised Gains   1,812,183  2,396,552 
The accounting policies on pages 56 to 57 and the notes on pages 62 to 69 form part of the financial statements.
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alance Sheet
As at 31 December 2008
  Note  2008  2007 
   €  €
Tangible Assets 1  24,684,505   24,657,277 
Current Assets   
Debtors and Prepayments 6  1,664,448   1,703,351 
Stock of Stationery   3,451   4,707 
Cash at Bank and in Hand 12  1,758,387   1,711,782 
Short Term Deposits   4,104,265   2,153,665 
    7,530,551   5,573,505 
Creditors - Amounts falling due within one year
Creditors and Accruals 7  5,487,926   4,975,835 
Mortgage 13  340,000   340,000 
    5,827,926   5,315,835 
Net Current Assets   1,702,625   257,670 
Long Term Liabilities
Mortgage 13  11,900,000   12,240,000 
TOTAL NET ASSETS   14,487,130   12,674,947 
Financed by 
Income and Expenditure Reserve 11  14,487,130   12,674,947 
    14,487,130   12,674,947
 
Pat O’Mahony Maureen Windle 
Chairman Board Member
The accounting policies on pages 56 to 57 and the notes on pages 62 to 69 form part of the financial statements.
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Cash Flow Statement
For the year ended 31 December 2008
  Note  2008  2007 
   €  €
Reconciliation of surplus to net cash inflow from operating activities 
Surplus for Year  1,812,183 2,396,552
Depreciation Charge  1,606,304 1,247,081
(Increase)/Decrease in Debtors  38,903 (317,023)
(Increase)/Decrease in Stocks  1,256 333
Increase/(Decrease) in Creditors - amounts falling due within one year  512,091 395,890
Deposit Interest   (121,894) (79,717)
Bank Interest and Charges  528,025 540,444
Loss/(Gain) on Disposal of Fixed Assets  374 44,092
Net Cash Inflow from Operating Activities  4,377,242 4,227,652
Cash Flow Statement
Net Cash Inflow from Operating Activities  4,377,242 4,227,652
Return on Investments and Servicing of Finance 8 (406,131) (460,727)
Capital Expenditure 8 (1,633,906) (3,418,322)
Management of Liquid Resources 8 (1,950,600) 1,109,722
Financing 8 (340,000) (340,000)
Increase/(Decrease) in Cash   46,605 1,118,325
Reconciliation of net cash flow to movement in net debt
Increase/(Decrease) In Cash  46,605 1,118,325
Increase/(Decrease) In Short Term Deposits  1,950,600 (1,109,722)
(Increase)/Decrease In Long Term Finance  340,000 340,000
Change In Net Debt  2,337,205 348,603
Net Debt at start of year  (8,714,553) (9,063,156)
Net Debt at end of year 9 (6,377,348) (8,714,553)
The accounting policies on pages 56 to 57 and the notes on pages 62 to 69 form part of the financial statements.
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Notes to the Financial Statements 
For the year ended 31 December 2008
1 TANGIBLE ASSETS 
  Fixtures and Computer  Leasehold  Improvements 
  Fittings Equipment Improvements To Premises Premises Total 
  € € € € € €
 Cost
 Balance as at 1 January 2008  683,180   5,667,919   502,445   2,894,943   20,383,000  30,131,487
 Additions for the year  238,226   1,019,403  –   376,659  –  1,634,288
 Disposals for the year (21,068) –  – –  –  (21,068)
 As at 31 December 2008  900,338   6,687,322   502,445   3,271,602   20,383,000  31,744,707
 Depreciation
 Balance as at 1 January 2008  291,832   4,767,972   149,478   264,928  –  5,474,210
 Charge for the year  164,482   935,714   50,245   455,863  –  1,606,304
 Disposals for the year (20,312) –  –  –  –  (20,312)
 As at 31 December 2008  436,002   5,703,686   199,723   720,791  –  7,060,202
 Net Book value  
 at 31 December 2008  464,336   983,636   302,722   2,550,811   20,383,000  24,684,505
 Net Book value  
 at 1 January 2008  391,348   899,947   352,967   2,630,015   20,383,000  24,657,277
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2 INCOME
   2008 2007 
   € €
 Fee Income
 Clinical Trials   151,762   118,081 
 Human Medicine - National Fees   6,459,620   6,090,886 
 Human Medicine - European Fees   6,837,485   6,025,588 
 Veterinary Medicine - National Fees   1,076,667   1,150,323 
 Veterinary Medicine - European Fees   915,986   854,874 
 Compliance Department   3,087,380   2,853,490 
 Medical Devices   175,356   146,707 
    18,704,256   17,239,949 
 Other Income ( Note 3 )   5,220,407   5,073,029 
 Total Income   23,924,663   22,312,978
 
Certain fees, totalling €13,460,099, are required by law to be disposed of in accordance with the directions of the Minister 
for Finance.
3 OTHER INCOME
   2008 2007 
   € €
 Dept Of Health & Children Funding   4,993,212   4,924,000 
 IT Income   5,000   13,000 
 Conference Fee Income   100,675   88,402 
 Deposit Interest   121,894   79,717 
 (Loss)/Gain on Disposal of Fixed Assets  (374) (44,092)
 Miscellaneous  –   12,002 
    5,220,407  5,073,029
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4 SALARIES AND WAGES
   2008 2007 
   € €
 Salaries and Wages   13,971,860   12,113,971 
 Social Welfare Costs   1,283,827   1,125,427 
    15,255,687   13,239,398
 
 The average number of staff employed during the year was 260 (2007 - 234).
 Staff employed at 31 December 2008 can be analysed across the following departments : 
   2008 2007
 Medical Technical   18   15 
 Pharmaceutical Technical   32   28 
 Veterinary Technical   12   11 
 Compliance Technical   18   18 
 Medical Devices Technical   17   14 
 Enforcement Technical   9   8
 Scientific Technical   1   1 
 Blood Directive Technical   4   5 
 Controlled Drugs Technical   3   2 
 Tissues Technical   2   2 
 Chief Executive and Corporate   33   30 
 Operational Staff   106   94 
 Pensioners   11   10 
    266   238
Notes to the Financial Statements 
(continued)
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5 OPERATING COSTS  
   2008 2007 
   € €
 Accommodation Costs   1,050,907   1,096,121 
 Travel, Representation and Training   1,156,870   1,153,890 
 Bank Charges and Interest   528,025   540,444 
 Legal & Professional Fees   361,706   591,150 
 Stationery, Publications and Postage   422,104   396,123 
 Other Operating Costs   2,368,394   2,174,063 
    5,888,006   5,951,791
6 DEBTORS (ALL DuE WITHIN ONE yEAR)
   2008 2007 
   € €
 Trade Debtors   1,160,040   1,340,493 
 Prepayments   322,693   266,401 
 Other Debtors   181,715   96,457 
    1,664,448   1,703,351
7 CREDITORS (AMOuNTS fALLING DuE WITHIN ONE yEAR)  
   2008 2007 
   € €
 Trade Creditors   561,913   702,718 
 Accruals   4,506,106   3,842,994 
 Revenue   419,907   430,123 
    5,487,926   4,975,835
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8 GROSS CASH fLOWS
   2008 2007 
   € €
 Returns on Investment and Servicing of Finance    
 Deposit Interest   121,894   79,717 
 Bank Interest and Charges  (528,025) (540,444)
   (406,131) (460,727)
 Capital Expenditure
 Payments to acquire Tangible Fixed Assets  (1,634,288) (3,418,354)
 Receipts from sales of Tangible Fixed Assets  382  32 
   (1,633,906) (3,418,322)
 Management of Liquid Resources
 (Increase)/Decrease in Short Term Deposits  (1,950,600) 1,109,722
   (1,950,600) 1,109,722
 Financing   
 Increase/(Decrease) in Long Term Finance  (340,000) (340,000)
   (340,000) (340,000)
9 ANALySIS Of CHANGES IN NET DEBT  
  As at  As at
  0/0/2008 Cashflow 3/2/2008
 Cash at Bank and in Hand   1,711,782  46,605  1,758,387 
 Short Term Deposits  2,153,665  1,950,600  4,104,265 
 Debt Due Within One Year (340,000) –  (340,000)
 Debt Due After One Year (12,240,000)  340,000  (11,900,000)
  (8,714,553)  2,337,205  (6,377,348)
10 ADMINISTRATION ExPENSES 
   2008 2007 
   € €
 Surplus for the year was calculated having charged : 
 Auditor’s Remuneration   18,500   18,500
Notes to the Financial Statements 
(continued)
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11 INCOME AND ExPENDITuRE RESERVES 
 The Income and Expenditure Reserve disclosed in the Balance Sheet on page 60 comprises the following :
   2008 2007 
   € €
 Retained Reserves   10,661,471   9,486,806 
 Staff Superannuation Contributions   3,825,659   3,188,141 
    14,487,130   12,674,947
12 CASH AND BANk BALANCES
   2008 2007 
   € €
 Current Account Balances   3,218   9,098 
 Deposit Account Balances   1,753,017   1,700,000 
 Cash on Hand   2,152   2,684 
    1,758,387   1,711,782
13 LONG TERM LIABILITIES
 Mortgage
 On 22 December 2004 the Board purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, 
Dublin 2. The purchase was financed by way of a mortgage, secured on the premises, of €20,400,000 over 20 years 
from Bank of Ireland Corporate Lending.
 The Irish Medicines Board is committed to making the following capital repayments on its mortgage :
   2008 2007 
   € €
 Within one year   340,000   340,000 
 Between one and five years   3,626,660   1,360,000 
 After five years   8,273,340   10,880,000 
    12,240,000   12,580,000
14 INTEREST RATE ExPOSuRE
 The IMB have taken all necessary steps to minimise its interest rate exposure by fixing two-thirds of the borrowings for 
a period of 10 years. The balance of the borrowings are fully offset by cash reserves. For 2009 it is estimated that the net 
borrowings for which an interest rate exposure may arise is €0.
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15 fINANCIAL COMMITMENTS 
   2008 2007 
   € €
 Operating Leases   
 Amounts payable during the next twelve months in respect of leases  
 which expire
 – within one year  –  – 
 – between one and five years  –  – 
 – after five years (in respect of Alexandra House)   285,984   236,000 
    285,984   236,000 
 The operating lease amount includes an annual commitment of €285,984 in respect of the Board’s premises at 
Alexandra House, Earlsfort Centre, Earlsfort Terrace, Dublin 2. As shown in note 13 above, the IMB purchased Kevin 
O’Malley House on 22 December 2004, which is why no further lease obligations exist in respect of that premises.
 On 22 December 2004 the IMB signed a leasehold interest with 17 years remaining in respect of the 5th floor, 
Alexandra House, Earlsfort Centre, Dublin 2.
16 CAPITAL COMMITMENTS
   2008 2007 
   € €
 Contracted For (Contract Signed)   430,000   110,000 
 Not Contracted For   230,000   65,000 
    660,000   175,000
17 BOARD REMuNERATION
   2008 2007 
   € €
 Chairman’s Salary   25,435   26,087 
 Board Members’ Travel Expenses   8,486   8,645 
    33,921   34,732 
18 STAff REMuNERATION
   2008 2007 
   € €
 Chief Executive’s Remuneration   169,670   157,747 
 (Stated net of Superannuation Contributions )   
   169,670   157,747
Notes to the Financial Statements 
(continued)
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19 RELATED PARTy TRANSACTIONS
 There have been no transactions with related parties which require disclosure under Financial Reporting Standard 8.
20 PROMPT PAyMENT Of ACCOuNTS 
 The Irish Medicines Board (IMB) confirms that it is complying with EU law in relation to prompt payments of account.
21 ExCHANGE RATES
 The exchange rates used in preparing these financial statements were as follows :
 2008 €1 = STG £0.9525
 2007 €1 = STG £0.73335
22 PROVISIONS
 The Board has been notified of a number of legal proceedings or potential proceedings. The information usually 
required by FRS 12 Provisions, contingent liabilities and contingent assets is not disclosed as the Board believes that to 
do so would be prejudicial to the outcome.
23 APPROVAL Of fINANCIAL STATEMENTS
 The financial statements were approved by the Board on 29 April 2009.
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Management Committee
Mr. Pat O’Mahony – Chief Executive
Dr. J. Gabriel Beechinor – Director of Veterinary Medicines
Dr. Joan Gilvarry – Director of Human Medicines 
Mr. John Lynch – Director of Compliance
Ms. Suzanne McDonald – Director of Information 
Technology and Change Management
Dr. J. Michael Morris – Senior Scientific Advisor
Ms. Ann O’Connor – Medical Devices Director
Ms. Rita Purcell – Director of Finance and Corporate Affairs
 
Advisory Committee for Human Medicines
Dr. Brendan Buckley – Chairman
Dr. Mary Horgan
Dr. Kevin Connolly
Prof. John Kelly
Dr. Pat Sullivan
Dr. Bernard Silke
Prof. Ted Dinan
Mr. Tom McGuinn
Ms. Eugenie Canavan
Dr. Paul Browne
Dr. Desmond Corrigan
Dr. Íde Delargy
 
Advisory Committee for Veterinary Medicines 
Mr. Pat Brangan - Chairman
Mr. Tom McGuinn
Dr. Rory Breathnach
Ms. Eugenie Canavan
Dr. Thomas Barragry
Dr. Anne Cullinane
Mr. Joseph Britton
Mr. Matt Browne
Mr. Michael Clancy
Dr. Hamish D. Rodger
Dr. Donal Sammin
 
Advisory Committee for Medical Devices
Mr. Wilfrid J. Higgins – Chairman
Dr. Geoffrey Chadwick
Ms. Maureen D’Arcy
Dr. John Keogh
Prof. Robert McConnell
Dr. Brendan Cormack
Dr. Tim McGloughlin
Ms. Aideen Murphy
Dr. John O’Mullane
Ms. Maebh Smith
Prof. W. Arthur Tanner
Prof. Wil van der Putten
 
Appendix I : 
Management Committee Members and Committees
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Clinical Trial Sub-Committee of Advisory Committee 
for Human Medicines
Dr. Patrick Sullivan – Chairman
Dr. Tom Pierce
Prof. David Bouchier-Hayes
Dr. John Taaffe
Dr. Paul Browne
Prof. Ted Dinan
Prof. Sidney Lowry
Dr. Brian Cantwell
Experts Sub-Committee of the Advisory Committee 
for Human Medicines
Dr. Brendan Buckley
Dr. Mary Horgan
Dr. Brion Sweeney
Dr. Colin Buckley
Dr. Íde Delargy
Dr. Stephen Flint
Dr. Lorraine Kyne
Dr. Owen Hensey
Dr. Owen Carey
Dr. Kevin Connolly
Dr. Frank Murray
Dr. Mary Keogan
Dr. Kevin Kelleher
Dr. Linda Fenelon
Dr. John McCaffrey
Dr. Noreen Dowd
Dr. Patricia McCormack
Dr. Stephen Eustace
Dr. Douglas Veale
Dr. Joseph Galvin
Prof. Michael Fitzgerald
Prof. Brian Shephard
Dr. Tim Fulcher
Prof. David Kerins
Dr. Donal Brosnahan
Dr. Mark Ledwidge
Mr. Ashley Poynton
Dr. Yvonne O’Meara
Prof. Aidan McCormick
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Appendix II : 
Glossary
ACE Inhibitors  Inhibitors of Angiotensin-Converting 
Enzyme
CD Controlled drugs
CHMP Committee for Human Medicinal 
Products
COEn Compliance and Enforcement Working 
Group
CVMP Committee for Veterinary Medicinal 
Products 
DCP Decentralised Procedure 
E2B International Standardised format for 
Electronic Reporting of Adverse Reactions
EEA European Economic Area 
EMEA European Medicines Agency
EuDAMED European Database for Medical Devices
FDA Food and Drug Administration 
GCP Good clinical practice 
GDP Good distribution practice 
GMP Good manufacturing practice
ICSRs Individual Case Safety Reports
IMB Irish Medicines Board
IVD In-vitro diagnostic 
MAHs Marketing authorisation holders
MEDDEV  European Commission DG Enterprise 
& Industry – Medical Devices Guidance 
Document
MERIT Group Medical Emergency Responders 
Integration & Training 
MIMS Monthly Index of Medical Specialties 
MR Mutual recognition 
nBOG Notified Body Operations Group
nHO National Haemovigilance Office
nSAI National Standards Authority of Ireland
OMCL Official Medicines Control Laboratories 
PA Product Authorisation 
PhV Pharmacovigilance 
POCT Point of Care Testing 
QMS Quality Management System
RIO Regulatory Information Online 
SuSARs Serious, Unexpected, Suspect Adverse 
Reactions
VPA Veterinary Product Authorisation 
WHO World Health Organisation 

Kevin O’Malley House 
Earlsfort Centre 
Earlsfort Terrace 
Dublin 2
Tel: +353 1 676 4971 
Fax: +353 1 676 7836 
Email: imb@imb.ie 
Web: www.imb.ie
